title,url,time_published,summary,ticker,relevance_score,ticker_sentiment_score,ticker_sentiment_label
LILLY'S OLUMIANT®  ( BARICITINIB )  NOW AUTHORIZED IN CANADA FOR ADULTS WITH SEVERE ALOPECIA AREATA,https://www.newswire.ca/news-releases/lilly-s-olumiant-r-baricitinib-now-authorized-in-canada-for-adults-with-severe-alopecia-areata-871746601.html,2024-01-30 13:30:00,"• 17-22% of patients taking OLUMIANT 2 mg/day and 32-35% of patients taking OLUMIANT 4 mg/day achieved 80% or more scalp hair coverage, compared to 3-5% taking placebo. • Additionally, 11-13% of patients taking OLUMIANT 2 mg/day and 24-26% of patients taking OLUMIANT 4 mg/day achieved 90% or ...",INCY,0.058259,0.085122,Neutral
Incyte  ( INCY )  Banks on Opzelura as Jakafi Faces Competition,https://www.zacks.com/stock/news/2216446/incyte-incy-banks-on-opzelura-as-jakafi-faces-competition,2024-01-26 14:12:00,Incyte (INCY) is likely to rebound in 2024 on the solid growth of Opzelura and additional label expansions.,INCY,0.400531,0.088188,Neutral
"Tr1X, Inc. Announces $75 Million Series A Financing to Develop Best-in-Class Universal Allogeneic Regulatory T  ( Treg )  and CAR-Treg Cell Therapies to Treat and Potentially Cure Autoimmune and Inflammatory Diseases",https://www.prnewswire.com/news-releases/tr1x-inc-announces-75-million-series-a-financing-to-develop-best-in-class-universal-allogeneic-regulatory-t-treg-and-car-treg-cell-therapies-to-treat-and-potentially-cure-autoimmune-and-inflammatory-diseases-302036679.html,2024-01-17 13:30:00,"Tr1X, Inc. Announces $75 Million Series A Financing to Develop Best-in-Class Universal Allogeneic Regulatory T ( Treg ... PR ...",INCY,0.022202,0.061013,Neutral
"IDEAYA Biosciences, Inc.  ( IDYA )  Moves 7.6% Higher: Will This Strength Last?",https://www.zacks.com/stock/news/2209958/ideaya-biosciences-inc-idya-moves-76-higher-will-this-strength-last,2024-01-15 12:03:00,"IDEAYA Biosciences, Inc. (IDYA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.",INCY,0.580018,-0.088023,Neutral
"Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations - Aclaris Therapeutics  ( NASDAQ:ACRS ) ",https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36581090/analyst-highlights-aclaris-therapeutics-encouraging-efficacy-for-eczema-candidate-b,2024-01-10 20:12:51,"Wednesday, Aclaris Therapeutics Inc ACRS released topline results from its Phase 2b study of ATI-1777, an investigational topical ""soft"" JAK 1/3 inhibitor, in patients with mild to severe atopic dermatitis ( eczema ) .",INCY,0.24289,0.499336,Bullish
"Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030 - Ambrx Biopharma  ( NASDAQ:AMAM ) , Amgen  ( NASDAQ:AMGN ) ",https://www.benzinga.com/pressreleases/24/01/g36558906/global-oncology-cancer-drugs-market-revenue-projected-to-surpass-289-billion-by-2030,2024-01-09 15:25:00,"PALM BEACH, Fla., Jan. 09, 2024 ( GLOBE NEWSWIRE ) -- FN Media Group News Commentary - According to the report titled ""Aging in the United States,"" published by the Population Reference Bureau, ""the number of Americans aged 65 and older is projected to increase more than double over 95 million ...",INCY,0.038937,0.095682,Neutral
Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors,https://www.prnewswire.com/news-releases/oncolytics-biotech-appoints-patricia-s-andrews-to-its-board-of-directors-302029215.html,2024-01-09 12:00:00,"SAN DIEGO and CALGARY, AB, Jan. 9, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. ( NASDAQ: ONCY ) ( TSX: ONC ) , a clinical-stage immunotherapeutics company focused on oncology, today announced the appointment of Patricia S. Andrews to its Board of Directors ( the ""Board"" ) .",INCY,0.116914,0.063616,Neutral
Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors,https://www.newswire.ca/news-releases/oncolytics-biotech-r-appoints-patricia-s-andrews-to-its-board-of-directors-818628389.html,2024-01-09 12:00:00,"SAN DIEGO and CALGARY, AB, Jan. 9, 2024 /CNW/ -- Oncolytics Biotech® Inc. ( NASDAQ: ONCY ) ( TSX: ONC ) , a clinical-stage immunotherapeutics company focused on oncology, today announced the appointment of Patricia S. Andrews to its Board of Directors ( the ""Board"" ) .",INCY,0.116914,0.063616,Neutral
Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in ... - PR Newswire,https://www.prnewswire.com/apac/news-releases/innovent-dosed-first-participant-in-phase-3-clinical-study-glory-2-of-mazdutide-ibi362-higher-dose-9-mg-in-chinese-adults-with-obesity-302024184.html,2024-01-02 00:02:43,Innovent Dosed First Participant in Phase 3 Clinical Study ( GLORY-2 ) of Mazdutide ( IBI362 ) Higher Dose 9 mg in ... PR ...,INCY,0.076765,0.028572,Neutral
Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in ... - PR Newswire,https://www.prnewswire.com/news-releases/innovent-dosed-first-participant-in-phase-3-clinical-study-glory-2-of-mazdutide-ibi362-higher-dose-9-mg-in-chinese-adults-with-obesity-302024183.html,2024-01-02 00:00:00,Innovent Dosed First Participant in Phase 3 Clinical Study ( GLORY-2 ) of Mazdutide ( IBI362 ) Higher Dose 9 mg in ... PR ...,INCY,0.076765,0.028572,Neutral
THE SKIN OF COLOR SOCIETY  ( SOCS )  REPORTS A BANNER YEAR OF PROGRESS TOWARD GREATER DIVERSITY & INCLUSION IN DERMATOLOGY AND HEALTH EQUITY FOR PATIENTS OF COLOR,https://markets.businessinsider.com/news/stocks/the-skin-of-color-society-socs-reports-a-banner-year-of-progress-toward-greater-diversity-inclusion-in-dermatology-and-health-equity-for-patients-of-color-1032928334,2023-12-27 15:10:00,THE SKIN OF COLOR SOCIETY (SOCS) REPORTS A BANNER YEAR OF PROGRESS TOWARD GREATER DIVERSITY & INCLUSION IN DERMATOLOGY AND HEALTH EQUITY FOR PATIENTS OF COLOR ...,INCY,0.052226,0.239708,Somewhat-Bullish
Innovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertension - PR Newswire,https://www.prnewswire.com/apac/news-releases/innovent-and-sanegenebio-enter-strategic-collaboration-to-develop-sirna-drug-for-the-treatment-of-hypertension-302022227.html,2023-12-27 00:02:55,Innovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertension PR ...,INCY,0.078184,0.058635,Neutral
Innovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertension - Innovent Biologics  ( OTC:IVBIY ) ,https://www.benzinga.com/pressreleases/23/12/n36392752/innovent-and-sanegenebio-enter-strategic-collaboration-to-develop-sirna-drug-for-the-treatment-of-,2023-12-27 00:00:00,"ROCKVILLE, Md. and SUZHOU, China, Dec. 26, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ( ""Innovent"" ) ( HKEX: 01801 ) , a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ...",INCY,0.079392,0.058784,Neutral
Innovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertension ... - PR Newswire,https://www.prnewswire.com/news-releases/innovent-and-sanegenebio-enter-strategic-collaboration-to-develop-sirna-drug-for-the-treatment-of-hypertension-302022226.html,2023-12-27 00:00:00,Innovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertension ... PR ...,INCY,0.078184,0.058635,Neutral
Alopecia Market Size Is Expected To Reach $7.8 Billion In 2028 At A CAGR Of 7.9% As Per The Business Research Company's Alopecia Global Market Report 2024,https://www.benzinga.com/pressreleases/23/12/g36286287/alopecia-market-size-is-expected-to-reach-7-8-billion-in-2028-at-a-cagr-of-7-9-as-per-the-business,2023-12-18 16:30:00,"LONDON, Dec. 18, 2023 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Alopecia Global Market Report 2024, the alopecia market has witnessed robust growth in recent years, with the market size surging from $5.28 billion in 2023 to $5.76 billion in 2024, showcasing an impressive ...",INCY,0.054359,0.211012,Somewhat-Bullish
Innovent Announces Publication of Mazdutide  ( IBI362 )  Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications,https://www.prnewswire.com/apac/news-releases/innovent-announces-publication-of-mazdutide-ibi362-phase-2-full-results-in-chinese-patients-with-overweight-or-obesity-in-nature-communications-302017400.html,2023-12-18 00:00:00,Innovent Announces Publication of Mazdutide ( IBI362 ) Phase 2 Full Results in Chinese Patients with Overweight or ... PR ...,INCY,0.069428,0.056716,Neutral
Innovent Announces Publication of Mazdutide  ( IBI362 )  Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications,https://www.prnewswire.com/news-releases/innovent-announces-publication-of-mazdutide-ibi362-phase-2-full-results-in-chinese-patients-with-overweight-or-obesity-in-nature-communications-302017328.html,2023-12-18 00:00:00,Innovent Announces Publication of Mazdutide ( IBI362 ) Phase 2 Full Results in Chinese Patients with Overweight or ... PR ...,INCY,0.069428,0.056716,Neutral
What's Up With Incyte Stock Lately? - Incyte  ( NASDAQ:INCY ) ,https://www.benzinga.com/news/23/12/36205223/whats-up-with-incyte-stock-lately,2023-12-12 20:33:26,"Incyte Corporation INCY shares are trading higher on Tuesday. The stock has risen rapidly since Monday. Here's what has happened. What To Know: Prior to the stock's recent price spike, shares had largely consolidated over November.",INCY,0.870266,0.465567,Bullish
Sarepta Therapeutics  ( SRPT )  Up 4.5% Since Last Earnings Report: Can It Continue?,https://www.zacks.com/stock/news/2192446/sarepta-therapeutics-srpt-up-45-since-last-earnings-report-can-it-continue,2023-12-01 16:31:43,Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,INCY,0.21686,0.026622,Neutral
Why Is Incyte  ( INCY )  Down 1.8% Since Last Earnings Report?,https://www.zacks.com/stock/news/2191659/why-is-incyte-incy-down-18-since-last-earnings-report,2023-11-30 16:31:01,Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,INCY,0.450266,0.147121,Neutral
Innovent's MSCI ESG Rating Upgraded to A,https://www.prnewswire.com/apac/news-releases/innovents-msci-esg-rating-upgraded-to-a-302001857.html,2023-11-30 12:02:11,"ROCKVILLE, Md. and SUZHOU, China, Nov. 30, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ( Innovent ) ( HKEX: 01801 ) , a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ...",INCY,0.065268,0.057438,Neutral
GMAB: 3 Biotech Stocks Flowing With Investment Potential,https://stocknews.com/news/gmab-incy-orgo-3-biotech-stocks-flowing-with-investment-potential/,2023-11-24 15:24:40,"Despite broader economic challenges, the biotech industry thrives due to consistent innovation and steady demand. An aging population and the need for high-quality treatments for rare and common diseases back the optimism surrounding the industry.",INCY,0.196725,0.21808,Somewhat-Bullish
Mesoblast  ( MESO )  Up on Deal With BMT CTN to Develop GVHD Drug,https://www.zacks.com/stock/news/2188369/mesoblast-meso-up-on-deal-with-bmt-ctn-to-develop-gvhd-drug,2023-11-23 14:27:00,"Mesoblast (MESO) partners with Blood and Marrow Transplant Clinical Trials Network to develop a pivotal study on its lead candidate, Ryoncil, for acute graft versus host disease. The stock rises 11%.",INCY,0.247838,0.231819,Somewhat-Bullish
"The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma | DelveInsight",https://www.prnewswire.com/news-releases/the-evolving-market-dynamics-of-b-cell-lymphomas-diffuse-large-b-cell-lymphoma-follicular-lymphoma-chronic-lymphocytic-leukemia-mantle-cell-lymphoma-marginal-zone-lymphoma-waldenstrom-macroglobulinemia-and-burkitt-lymphoma--301995626.html,2023-11-22 22:01:00,"The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic ... PR ...",INCY,0.013173,0.040164,Neutral
MorphoSys  ( MOR )  Down 22% on Mixed Data From Myelofibrosis Study,https://www.zacks.com/stock/news/2188101/morphosys-mor-down-22-on-mixed-data-from-myelofibrosis-study,2023-11-22 18:48:00,"Though data from the late study shows that treatment with MorphoSys' (MOR) combination therapy met its primary goal, it did not meet a secondary endpoint.",INCY,0.284861,0.165816,Somewhat-Bullish
"Goldman Sachs Downgrades Incyte Amid Concerns Over Jakafi Studies, Competitiveness - Incyte  ( NASDAQ:INCY ) ",https://www.benzinga.com/analyst-ratings/analyst-color/23/11/35902449/goldman-sachs-downgrades-incyte-amid-concerns-over-jakafi-studies-competitiveness,2023-11-21 20:05:45,"Goldman Sachs downgraded Incyte Corp INCY, citing continued uncertainty around Jakafi ( Ruxolitinib ) lifecycle management ahead of the mid-27/late-28 EU/US losses-of-exclusivity ( LOEs ) .",INCY,0.800656,0.191691,Somewhat-Bullish
ROIV: Is Roivant Sciences  ( ROIV )  the Right Biotech Stock for Your Portfolio?,https://stocknews.com/news/roiv-incy-otsky-vrtx-is-roivant-sciences-roiv-the-right-biotech-stock-for-your/,2023-11-21 18:33:24,ROIV: Is Roivant Sciences ( ROIV ) the Right Biotech Stock for Your ... ...,INCY,0.057698,0.172997,Somewhat-Bullish
CURE Media Group® announces Jane Fonda as keynote speaker for the 2023 MPN Heroes® recognition program,https://www.benzinga.com/pressreleases/23/11/g35830363/cure-media-group-announces-jane-fonda-as-keynote-speaker-for-the-2023-mpn-heroes-recognition-progr,2023-11-16 15:38:42,"CURE and Incyte Corporation are proud to host the 2023 MPN Heroes recognition ceremony, an evening of gratitude and celebration of the heroes who have made a significant impact in the lives of patients with myeloproliferative neoplasms, or MPNs.",INCY,0.304679,0.593124,Bullish
MacroGenics  ( MGNX )  Q3 2023 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/11/07/macrogenics-mgnx-q3-2023-earnings-call-transcript/,2023-11-07 06:15:42,"MGNX earnings call for the period ending September 30, 2023.",INCY,0.014595,0.096245,Neutral
AbCellera Biologics  ( ABCL )  Q3 2023 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/11/03/abcellera-biologics-abcl-q3-2023-earnings-call-tra/,2023-11-03 09:30:54,"ABCL earnings call for the period ending September 30, 2023.",INCY,0.023146,0.065592,Neutral
Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update - Merus  ( NASDAQ:MRUS ) ,https://www.benzinga.com/pressreleases/23/11/g35576447/merus-announces-financial-results-for-the-third-quarter-2023-and-provides-business-update,2023-11-02 20:12:47,- Petosemtamab in combination with Keytruda 1L initial interim clinical data planned for 1H24; 2L+ HNSCC monotherapy clinical update planned 2024 - Zeno interim clinical data continue to show robust efficacy in NRG1+ NSCLC and PDAC: Sufficient clinical data expected in 1H24 to support potential ...,INCY,0.090389,0.042163,Neutral
"Incyte  ( INCY )  Beats on Q3 Earnings, Misses Revenue Estimates",https://www.zacks.com/stock/news/2175739/incyte-incy-beats-on-q3-earnings-misses-revenue-estimates,2023-10-31 16:14:00,"Incyte's (INCY) third-quarter 2023 earnings beat estimates, while revenues miss the same. The company tightens Jakafi net product revenue guidance for 2023.",INCY,0.513062,0.125213,Neutral
Incyte  ( INCY )  Surpasses Q3 Earnings Estimates,https://www.zacks.com/stock/news/2175181/incyte-incy-surpasses-q3-earnings-estimates,2023-10-31 12:15:08,"Incyte (INCY) delivered earnings and revenue surprises of 0.92% and 5.58%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?",INCY,0.405651,0.120516,Neutral
"Drug, Biotech Stocks' Q3 Earnings Due on Oct 31: AMGN, PFE, INCY",https://www.zacks.com/stock/news/2174650/drug-biotech-stocks-q3-earnings-due-on-oct-31-amgn-pfe-incy,2023-10-30 15:37:00,"Let's take a look at three biotech/drug companies, AMGN, PFE and INCY, slated to release quarterly results on Oct 31.",INCY,0.388879,0.136578,Neutral
Incyte  ( INCY )  to Report Q3 Earnings: What's in the Cards?,https://www.zacks.com/stock/news/2173871/incyte-incy-to-report-q3-earnings-whats-in-the-cards,2023-10-27 15:36:00,Higher sales of lead drug Jakafi and incremental sales of newly approved drugs are likely to have boosted Incyte's (INCY) top line during the third quarter of 2023.,INCY,0.722509,0.243069,Somewhat-Bullish
Sarepta Therapeutics  ( SRPT )  May Report Negative Earnings: Know the Trend Ahead of Q3 Release,https://www.zacks.com/stock/news/2171700/sarepta-therapeutics-srpt-may-report-negative-earnings-know-the-trend-ahead-of-q3-release,2023-10-25 14:02:26,Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,INCY,0.174272,-0.002844,Neutral
"Elevar Therapeutics Names Brian Cunningham Vice President of Sales and Kenneth Rankin Vice President of Market Access, Strengthening Commercial Leadership in Buildup to Launch",https://www.benzinga.com/pressreleases/23/10/g35372500/elevar-therapeutics-names-brian-cunningham-vice-president-of-sales-and-kenneth-rankin-vice-preside,2023-10-23 12:45:00,"FORT LEE, N.J., Oct. 23, 2023 ( GLOBE NEWSWIRE ) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, ...",INCY,0.04882,-0.022905,Neutral
INCY: 3 Revolutionary Biotech Stocks Worth Investing In,https://stocknews.com/news/incy-plx-eq-repl-sndx-3-revolutionary-biotech-stocks-worth-investing-in/,2023-10-18 17:30:32,"The biotech industry's soaring growth owes much to the flourishing realm of personalized medicine, the rise of orphan drugs, innovative biotech tools, and unwavering government support.",INCY,0.247278,0.232779,Somewhat-Bullish
Incyte  ( NASDAQ:INCY )  Downgraded to Buy at StockNews.com,https://www.defenseworld.net/2023/10/17/incyte-nasdaqincy-downgraded-to-buy-at-stocknews-com-2.html,2023-10-17 08:31:04,StockNews.com cut shares of Incyte ( NASDAQ:INCY - Free Report ) from a strong-buy rating to a buy rating in a report issued on Monday. Several other analysts also recently issued reports on the company.,INCY,0.824067,0.36656,Bullish
"Large Granular Lymphocyte Leukemia Market is Projected to Grow During the Study Period  ( 2019-2032 ) , Assesses DelveInsight | Key Companies - Bristol Myers Squibb, Innate Pharma, Kymera Therapeutics, EUSA Pharma, Abcuro, Dren Bio, Novotech",https://www.prnewswire.com/news-releases/large-granular-lymphocyte-leukemia-market-is-projected-to-grow-during-the-study-period-20192032-assesses-delveinsight--key-companies---bristol-myers-squibb-innate-pharma-kymera-therapeutics-eusa-pharma-abcuro-dren-bio-n-301957023.html,2023-10-16 21:01:00,"Large Granular Lymphocyte Leukemia Market is Projected to Grow During the Study Period ( 2019-2032 ) , Assesses ... PR ...",INCY,0.025845,-0.026539,Neutral
AMGN: Exploring the Upside Potential of 3 Biotech Stocks,https://stocknews.com/news/amgn-incy-alks-exploring-the-upside-potential-of-3-biotech-stocks/,2023-10-16 13:08:43,"The biotech industry is well-positioned for steady growth, owing to rapid advancements in drug developments and the growing demand to treat chronic diseases.",INCY,0.189422,0.232294,Somewhat-Bullish
Knight Therapeutics Announces CMED Price Approval of Minjuvi® in Brazil,https://investingnews.com/knight-therapeutics-announces-cmed-price-approval-of-minjuvi-r-in-brazil/,2023-10-16 12:06:20,"Knight Therapeutics Inc., ( TSX: GUD ) ( ""Knight"" ) a pan-American ( ex-USA ) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has received pricing approval for Minjuvi® ( tafasitamab ) from the Drugs Market Regulation Chamber ( ""CMED"" ) .",INCY,0.203337,0.246533,Somewhat-Bullish
Incyte  ( INCY )  Stock Plummets 29.6% Year to Date: Here's Why,https://www.zacks.com/stock/news/2165826/incyte-incy-stock-plummets-296-year-to-date-heres-why,2023-10-13 16:44:00,Incyte (INCY) loses 29.6% year-to-date as competition increases for Jakafi and the company suffers pipeline setbacks.,INCY,0.622414,0.12693,Neutral
AbbVie's  ( ABBV )  Rinvoq Meets Key Goal in Phase II Vitiligo Study,https://www.zacks.com/stock/news/2165416/abbvies-abbv-rinvoq-meets-key-goal-in-phase-ii-vitiligo-study,2023-10-13 11:02:00,AbbVie (ABBV) meets the primary goal in the phase II study evaluating Rinvoq in the treatment of adult patients with non-segmental vitiligo.,INCY,0.095327,0.196025,Somewhat-Bullish
Incyte  ( INCY )  Posts Upbeat Data From Phase II Vitiligo Study,https://www.zacks.com/stock/news/2165026/incyte-incy-posts-upbeat-data-from-phase-ii-vitiligo-study,2023-10-12 15:29:00,Incyte (INCY) announces new positive 52-week data from its mid-stage study of povorcitinib for the treatment of adult patients with extensive nonsegmental vitiligo.,INCY,0.402941,0.050447,Neutral
Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032,https://investingnews.com/global-car-t-cell-therapy-market-projected-to-reach-83-billion-by-2032/,2023-10-12 13:39:21,"FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines.",INCY,0.084796,0.028337,Neutral
Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil,https://investingnews.com/knight-therapeutics-announces-regulatory-submission-of-pemigatinib-in-brazil/,2023-10-10 21:11:41,"Knight Therapeutics Inc., ( TSX: GUD ) ( ""Knight"" ) a pan-American ( ex-USA ) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for pemigatinib to ANVISA, the Brazilian health regulatory ...",INCY,0.206811,0.249646,Somewhat-Bullish
Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil,https://www.globenewswire.com/news-release/2023/10/10/2757944/0/en/Knight-Therapeutics-Announces-Regulatory-Submission-of-Pemigatinib-in-Brazil.html,2023-10-10 20:45:00,"MONTREAL, Oct. 10, 2023 ( GLOBE NEWSWIRE ) -- Knight Therapeutics Inc., ( TSX: GUD ) ( ""Knight"" ) a pan-American ( ex-USA ) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for pemigatinib to ...",INCY,0.17824,0.244093,Somewhat-Bullish
"The Evolving Market Dynamics of Factor-based Bleeding Disorders: Hemophilia A, Hemophilia B, and Von Willebrand Disease | Key Analysis by DelveInsight",https://www.prnewswire.com/news-releases/the-evolving-market-dynamics-of-factor-based-bleeding-disorders-hemophilia-a-hemophilia-b-and-von-willebrand-disease--key-analysis-by-delveinsight-301950491.html,2023-10-09 21:01:00,"The Evolving Market Dynamics of Factor-based Bleeding Disorders: Hemophilia A, Hemophilia B, and Von Willebrand ... PR ...",INCY,0.018173,0.033264,Neutral
"Incyte  ( NASDAQ:INCY )  Downgraded to ""Buy"" at StockNews.com",https://www.defenseworld.net/2023/09/29/incyte-nasdaqincy-downgraded-to-buy-at-stocknews-com.html,2023-09-29 07:34:53,"Incyte ( NASDAQ:INCY - Get Free Report ) was downgraded by research analysts at StockNews.com from a ""strong-buy"" rating to a ""buy"" rating in a research report issued to clients and investors on Friday. Several other equities research analysts have also commented on the stock.",INCY,0.845894,0.448218,Bullish
"CAR T-cell Therapy for Multiple Myeloma Market to Observe Stunning Growth by 2032, Evaluates DelveInsight | Key Companies - Cartesian, Arcellx, Novartis, Bristol-Myers Squibb, CARsgen, Poseida, Juno, CRISPR, bluebird bio",https://www.prnewswire.com/news-releases/car-t-cell-therapy-for-multiple-myeloma-market-to-observe-stunning-growth-by-2032-evaluates-delveinsight--key-companies---cartesian-arcellx-novartis-bristol-myers-squibb-carsgen-poseida-juno-crispr-bluebird-bio-301937157.html,2023-09-25 21:01:00,"CAR T-cell Therapy for Multiple Myeloma Market to Observe Stunning Growth by 2032, Evaluates DelveInsight | Key ... PR ...",INCY,0.018757,0.024665,Neutral
REGN: Investors Keeping a Close Eye on These 3 Biotech Stocks,https://stocknews.com/news/regn-incy-cort-dbtx-investors-keeping-a-close-eye-on-these-3-biotech-stocks/,2023-09-25 15:20:17,"The biotech industry is fueled by an increasing number of orphan drug formulations and increasing investment in advanced technologies. Given the industry's steady growth prospects, investors could consider quality biotech stocks Regeneron Pharmaceuticals, Inc. ( REGN ) , Corcept Therapeutics ...",INCY,0.19677,0.176242,Somewhat-Bullish
StockNews.com Upgrades Incyte  ( NASDAQ:INCY )  to Strong-Buy,https://www.defenseworld.net/2023/09/23/stocknews-com-upgrades-incyte-nasdaqincy-to-strong-buy.html,2023-09-23 05:24:48,"Incyte ( NASDAQ:INCY - Get Free Report ) was upgraded by stock analysts at StockNews.com from a ""buy"" rating to a ""strong-buy"" rating in a research report issued to clients and investors on Thursday. A number of other analysts have also recently issued reports on the company.",INCY,0.841002,0.414314,Bullish
Former IBD 50 Stock Implodes As Its 'Prestige' Plan Goes Up In Smoke,https://www.investors.com/news/technology/rvnc-stock-collapses-as-prestige-plan-goes-up-in-smoke/,2023-09-19 15:53:00,"Revance Therapeutics ( RVNC ) is reversing course to stay competitive with AbbVie's ( ABBV ) market-leading aesthetics drug, Botox - and RVNC stock crashed Tuesday in response. The company said earlier this year it was going after ""prestige"" accounts with its Daxxify, the newest in a class of ...",INCY,0.074692,-0.061485,Neutral
Incyte  ( INCY )  Down on FDA Nod for Another Myelofibrosis Drug,https://www.zacks.com/stock/news/2152427/incyte-incy-down-on-fda-nod-for-another-myelofibrosis-drug,2023-09-19 12:24:00,Incyte (INCY) declines on potential competition for lead drug Jakafi from Ojjaara for the treatment of intermediate or high-risk myelofibrosis.,INCY,0.497733,-0.019451,Neutral
"Head and Neck Squamous Cell Carcinoma Market to Witness Upsurge in Growth by 2032, Assesses DelveInsight | Key Companies in the Market - Pfizer, Merck, Eisai, AstraZeneca, Innate, Roche, GlaxoSmithKline, BeiGene, IO Biotech, Incyte",https://www.prnewswire.com/news-releases/head-and-neck-squamous-cell-carcinoma-market-to-witness-upsurge-in-growth-by-2032-assesses-delveinsight--key-companies-in-the-market---pfizer-merck-eisai-astrazeneca-innate-roche-glaxosmithkline-beigene-io-biotech-incyt-301930322.html,2023-09-18 21:01:00,"Head and Neck Squamous Cell Carcinoma Market to Witness Upsurge in Growth by 2032, Assesses DelveInsight | Key ... PR ...",INCY,0.023146,0.04357,Neutral
"Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison - Incyte  ( NASDAQ:INCY ) , GSK  ( NYSE:GSK ) ",https://www.benzinga.com/analyst-ratings/analyst-color/23/09/34699111/anemia-advantage-for-gsks-blood-cancer-therapy-could-influence-market-share-despite,2023-09-18 17:59:46,"Friday, the FDA approved GSK plc's GSK Ojjaara ( momelotinib ) for intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis ( post-polycythemia vera and post-essential thrombocythaemia ) , in adults with anemia.",INCY,0.414559,0.344721,Somewhat-Bullish
How GSK's Newest Approval Sent This Market Leader To A 5-Year Low,https://www.investors.com/news/technology/incyte-stock-hits-five-year-low-as-gsk-looks-to-scoop-its-jakafi-market/,2023-09-18 16:03:00,Incyte Stock Hits Five-Year Low As GSK Looks To Scoop Its Jakafi ... Investor's Business Daily ...,INCY,0.5341,0.132728,Neutral
"Asthma Market is Predicted to Exhibit Remarkable Growth by 2032, Predicts DelveInsight | Key Companies to Look Out - GlaxoSmithKline, AstraZeneca, Sanofi, Roche, Amgen, Regeneron, Incyte, Areteia, Suzhou Connect, Cumberland, Pulmatrix",https://www.prnewswire.com/news-releases/asthma-market-is-predicted-to-exhibit-remarkable-growth-by-2032-predicts-delveinsight--key-companies-to-look-out---glaxosmithkline-astrazeneca-sanofi-roche-amgen-regeneron-incyte-areteia-suzhou-connect-cumberland-pulma-301927336.html,2023-09-14 21:01:00,"Asthma Market is Predicted to Exhibit Remarkable Growth by 2032, Predicts DelveInsight | Key Companies to Look Out ... PR ...",INCY,0.025929,0.084714,Neutral
"Acute Lymphocytic Leukemia Market to Accelerate Substantially by 2032, Assesses DelveInsight | Key Companies in the Market - Beam, Pfizer, Genentech, AbbVie, Fate, Roche, Ascentage, Janssen, Jazz, ADC, Kymera, Syndax, ImmunoGen",https://www.prnewswire.com/news-releases/acute-lymphocytic-leukemia-market-to-accelerate-substantially-by-2032-assesses-delveinsight--key-companies-in-the-market---beam-pfizer-genentech-abbvie-fate-roche-ascentage-janssen-jazz-adc-kymera-syndax-immunogen-301925772.html,2023-09-13 21:01:00,"Acute Lymphocytic Leukemia Market to Accelerate Substantially by 2032, Assesses DelveInsight | Key Companies in ... PR ...",INCY,0.021897,0.0,Neutral
SGIOY: 3 Biotech Stocks to Buy under $20,https://stocknews.com/news/sgioy-mgnx-acor-3-biotech-stocks-to-buy-under-20/,2023-09-11 15:53:09,SGIOY: 3 Biotech Stocks to Buy under ...,INCY,0.109956,0.196769,Somewhat-Bullish
Here's How Much You'd Have If You Invested $1000 in Eli Lilly a Decade Ago,https://www.zacks.com/stock/news/2146456/heres-how-much-youd-have-if-you-invested-1000-in-eli-lilly-a-decade-ago,2023-09-08 12:30:03,Holding on to popular or trending stocks for the long-term can make your portfolio a winner.,INCY,0.053629,0.024871,Neutral
Global Vitiligo Treatment Market 2023 - 2028: Ongoing Research and Advocacy Drive Progress,https://www.prnewswire.com/news-releases/global-vitiligo-treatment-market-2023---2028-ongoing-research-and-advocacy-drive-progress-301915850.html,2023-09-01 23:15:00,"DUBLIN, Sept. 1, 2023 /PRNewswire/ -- The ""Vitiligo Treatment Market, Size, Share, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis"" report has been added to ResearchAndMarkets.com's offering.",INCY,0.058615,0.0,Neutral
"MRNA: Which of These 3 Biotech Stocks Are a Buy, Sell, or Hold?",https://stocknews.com/news/mrna-fold-mgnx-mrk-incy-which-of-these-3-biotech-stocks-are-a-buy-sell/,2023-09-01 17:43:49,"While the first few months of the year witnessed volatility driven by increasing interest rates, an economic downturn, ongoing geopolitical uncertainties, regulatory changes under the Inflation Reduction Act, and persistent supply chain disruptions, biotech manufacturers are steadily regaining ...",INCY,0.087503,0.18513,Somewhat-Bullish
Why Is Incyte  ( INCY )  Down 0.7% Since Last Earnings Report?,https://www.zacks.com/stock/news/2143111/why-is-incyte-incy-down-07-since-last-earnings-report,2023-08-31 15:31:28,Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,INCY,0.482217,0.221574,Somewhat-Bullish
"Essential Thrombocythemia Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies to Look Out - Imago BioSciences, Incyte, Karyopharm, Novartis, PharmaEssentia, Celgene, Kartos, Sierra Oncology",https://www.prnewswire.com/news-releases/essential-thrombocythemia-market-to-witness-upsurge-in-growth-by-2032-predicts-delveinsight--key-companies-to-look-out---imago-biosciences-incyte-karyopharm-novartis-pharmaessentia-celgene-kartos-sierra-oncology-301912007.html,2023-08-30 21:01:00,"Essential Thrombocythemia Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies to ... PR ...",INCY,0.058188,0.109985,Neutral
AMGN: 3 Best Biotech Stocks for Health and Wealth,https://stocknews.com/news/amgn-vrtx-incy-repl-sndx-3-best-biotech-stocks-for-health-and-wealth/,2023-08-29 17:56:51,"Innovative biotech companies are making remarkable progress in creating novel medications and therapies for a diverse array of conditions, such as cancer, heart disease, and rare ailments. Encouraging trial outcomes and enhanced patient well-being are spurring the demand for continuous medical ...",INCY,0.164228,0.13575,Neutral
"Incyte  ( NASDAQ:INCY )  Downgraded by StockNews.com to ""Buy""",https://www.defenseworld.net/2023/08/29/incyte-nasdaqincy-downgraded-by-stocknews-com-to-buy.html,2023-08-29 07:44:46,StockNews.com lowered shares of Incyte ( NASDAQ:INCY - Free Report ) from a strong-buy rating to a buy rating in a report published on Monday. Other research analysts have also issued reports about the stock.,INCY,0.837604,0.444276,Bullish
"Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer - Editas Medicine  ( NASDAQ:EDIT ) , Medicenna Therapeutics  ( NASDAQ:MDNA ) ",https://www.benzinga.com/pressreleases/23/08/g34064855/medicenna-announces-the-appointment-of-jeff-caravella-as-chief-financial-officer,2023-08-28 11:00:57,"Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella's appointment demonstrates Medicenna's continuing commitment to establish its presence in Boston, the leading ...",INCY,0.039614,0.115287,Neutral
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer,https://www.globenewswire.com/news-release/2023/08/28/2732483/0/en/Medicenna-Announces-the-Appointment-of-Jeff-Caravella-as-Chief-Financial-Officer.html,2023-08-28 11:00:00,"Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations ...",INCY,0.050254,0.117592,Neutral
Navigating Deuruxolitinib's road: HSBC and Nomura weigh in on Sun Pharma's outlook,https://www.moneycontrol.com/news/business/markets/navigating-deuruxolitinibs-road-hsbc-and-nomura-weigh-in-on-suns-outlook-11247951.html,2023-08-24 03:05:14,"HSBC and Nomura maintain buy ratings, with HSBC increasing target price to Rs 1275 ( 13.5% from earlier ) and Nomura to Rs 1313 ( from Rs 1138 ) .",INCY,0.166743,-0.052008,Neutral
"If You Invested $1000 in Eli Lilly a Decade Ago, This is How Much It'd Be Worth Now",https://www.zacks.com/stock/news/2139535/if-you-invested-1000-in-eli-lilly-a-decade-ago-this-is-how-much-itd-be-worth-now,2023-08-23 12:30:04,Holding on to popular or trending stocks for the long-term can make your portfolio a winner.,INCY,0.05387,0.024879,Neutral
Medical Second Opinion Global Market to Register Stunning Growth at a CAGR of ~17% by 2028 | DelveInsight,https://www.prnewswire.com/news-releases/medical-second-opinion-global-market-to-register-stunning-growth-at-a-cagr-of-17-by-2028--delveinsight-301905294.html,2023-08-21 21:01:00,"The medical second opinion market is expanding rapidly due to the increasing frequency of malignancies, infectious diseases, genetic diseases, cardiovascular diseases, hematological diseases, orthopedic diseases, and other diseases around the world.",INCY,0.024347,-0.03954,Neutral
3 Under-the-Radar Biotech Stocks to Buy in 2023,https://www.fool.com/investing/2023/08/19/3-under-the-radar-biotech-stocks-to-buy-in-2023/,2023-08-19 11:40:00,All three biotech companies focus on oncology therapies.,INCY,0.04872,0.126979,Neutral
MacroGenics'  ( MGNX )  Shares Jump 19% in One Week: Here's Why,https://www.zacks.com/stock/news/2136295/macrogenics-mgnx-shares-jump-19-in-one-week-heres-why,2023-08-14 15:19:00,MacroGenics (MGNX) shares increase after it reported a surge in Q2 earnings per share. A $50-million milestone payment from Sanofi was also triggered last month.,INCY,0.219809,-0.160161,Somewhat-Bearish
MacroGenics  ( MGNX )  Q2 2023 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/08/09/macrogenics-mgnx-q2-2023-earnings-call-transcript/,2023-08-10 03:30:23,"MGNX earnings call for the period ending June 30, 2023.",INCY,0.007258,0.094481,Neutral
"Bladder Cancer Market Likely to Exhibit Substantial Growth, Assesses DelveInsight | Leading Companies - CicloMed, Bristol-Myers Squibb, CG Oncology, Merck, Eli Lilly and Company, UroGen, Ferring",https://www.prnewswire.com/news-releases/bladder-cancer-market-likely-to-exhibit-substantial-growth-assesses-delveinsight--leading-companies---ciclomed-bristol-myers-squibb-cg-oncology-merck-eli-lilly-and-company-urogen-ferring-301894332.html,2023-08-07 21:01:00,"Bladder Cancer Market Likely to Exhibit Substantial Growth, Assesses DelveInsight | Leading Companies - CicloMed ... PR ...",INCY,0.045439,-0.031842,Neutral
Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update,https://www.globenewswire.com/news-release/2023/08/07/2720163/37568/en/Merus-Announces-Financial-Results-for-the-Second-Quarter-2023-and-Provides-Business-Update.html,2023-08-07 20:26:00,- Petosemtamab granted Fast Track Designation for the treatment of patients with recurrent or metastatic head & neck squamous cell carcinoma ...,INCY,0.058188,0.025053,Neutral
"The Biotech Game Is Changing. Watch for Disruptions, Says RBC.",https://www.barrons.com/articles/biotech-stocks-changing-regulation-disruption-1b4b3ee,2023-08-04 20:33:00,"Disruptions in Biotech Could Shake Up the Stocks. Watch Out, Says ...",INCY,0.250386,-0.022243,Neutral
Incyte  ( NASDAQ:INCY )  Stock Rating Upgraded by StockNews.com,https://www.defenseworld.net/2023/08/04/incyte-nasdaqincy-stock-rating-upgraded-by-stocknews-com.html,2023-08-04 06:24:46,"Incyte ( NASDAQ:INCY - Get Free Report ) was upgraded by equities researchers at StockNews.com from a ""buy"" rating to a ""strong-buy"" rating in a research report issued to clients and investors on Wednesday. Several other equities research analysts have also commented on the stock.",INCY,0.784481,0.469581,Bullish
"Pancreatic Endocrine Tumor Market is Expected to Expand at a Healthy Growth Rate by 2032, Assesses DelveInsight | Key Companies - Merck, Theradex, SynerGene, Mirati, Novartis, Syntrix Biosystems, Eli Lilly, Boehringer Ingelheim",https://www.prnewswire.com/news-releases/pancreatic-endocrine-tumor-market-is-expected-to-expand-at-a-healthy-growth-rate-by-2032-assesses-delveinsight--key-companies---merck-theradex-synergene-mirati-novartis-syntrix-biosystems-eli-lilly-boehringer-ingelheim-301892397.html,2023-08-03 21:01:00,"Pancreatic Endocrine Tumor Market is Expected to Expand at a Healthy Growth Rate by 2032, Assesses DelveInsight ... PR ...",INCY,0.041466,-0.017808,Neutral
"Incyte's Jakafi Patent Expiry In 2028 Poses Challenge, Analyst Says New Treatments To Battle For Market Share - Incyte  ( NASDAQ:INCY ) ",https://www.benzinga.com/analyst-ratings/analyst-color/23/08/33498254/incytes-jakafi-patent-expiry-in-2028-poses-challenge-analyst-says-new-treatments-to,2023-08-01 20:31:02,"Incyte Corporation's INCY Q2 adjusted EPS reached $0.99, compared to $1.01 posted a year ago. Analysts had estimated $0.87. Q2 revenues increased by 25% Y/Y to $954.61 million, beating the consensus of $920.18 million.",INCY,0.544495,0.341713,Somewhat-Bullish
Incyte  ( INCY )  Beats on Q2 Earnings and Revenue Estimates,https://www.zacks.com/stock/news/2130522/incyte-incy-beats-on-q2-earnings-and-revenue-estimates,2023-08-01 14:05:00,"Incyte (INCY) reports impressive Q2 earnings on strong uptake in Jakafi and Opzelura sales. The company raises the bottom end of full-year guidance, setting a new range of $2.58-$2.63 billion.",INCY,0.605524,0.181687,Somewhat-Bullish
Incyte  ( INCY )  Beats Q2 Earnings and Revenue Estimates,https://www.zacks.com/stock/news/2130309/incyte-incy-beats-q2-earnings-and-revenue-estimates,2023-08-01 12:25:10,"Incyte (INCY) delivered earnings and revenue surprises of 13.79% and 3.74%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?",INCY,0.40348,0.143722,Neutral
Incyte beats estimates on high demand for cancer drug Jakafi,https://www.reuters.com/business/healthcare-pharmaceuticals/incyte-beats-estimates-high-demand-cancer-drug-jakafi-2023-08-01/,2023-08-01 12:23:00,Incyte beats estimates on high demand for cancer drug ...,INCY,0.38489,-0.150861,Somewhat-Bearish
"Stocks making the biggest moves premarket: Uber, Gap, Caterpillar & more",https://www.cnbc.com/2023/08/01/stocks-making-the-biggest-moves-premarket-uber-gap-cat.html,2023-08-01 12:11:06,"Despite missing Wall Street's revenue expectations, shares of Uber rose more than 4% after the ride-hailing giant offered rosy guidance for the third quarter.",INCY,0.124164,0.095192,Neutral
Morning Bid: August cools Wall St stocks,https://www.reuters.com/markets/us/global-markets-view-usa-2023-08-01/,2023-08-01 10:02:00,"A look at the day ahead in U.S. and global markets from Mike Dolan After notching a fifth straight month of gains for July ( .SPX ) , Wall St stocks looked set to step back on Tuesday as a deluge of corporate earnings hit this week and poor manufacturing soundings from around the world set a more ...",INCY,0.064104,0.074045,Neutral
"Drug, Biotech Stocks' Q2 Earnings Due on Aug 1: PFE, MRK & More",https://www.zacks.com/stock/news/2129900/drug-biotech-stocks-q2-earnings-due-on-aug-1-pfe-mrk-more,2023-07-31 13:58:00,"Let's look at five big biotech, pharma companies, PFE, MRK, VRTX, EXEL and INCY, slated to release quarterly results on Aug 1.",INCY,0.415927,0.104372,Neutral
"Urothelial Carcinoma Market is Expected to Showcase a Significant Growth by 2032, Assesses DelveInsight | Key Companies to Look Out - MedPacto, AstraZeneca, EMD Serono, Bayer, Merck, Bristol-Myers Squibb, Inovio, Seagen, Incyte",https://www.prnewswire.com/news-releases/urothelial-carcinoma-market-is-expected-to-showcase-a-significant-growth-by-2032-assesses-delveinsight--key-companies-to-look-out---medpacto-astrazeneca-emd-serono-bayer-merck-bristol-myers-squibb-inovio-seagen-incyte-301889003.html,2023-07-31 09:01:00,"Urothelial Carcinoma Market is Expected to Showcase a Significant Growth by 2032, Assesses DelveInsight | Key ... PR ...",INCY,0.072072,0.076494,Neutral
Incyte  ( INCY )  to Report Q2 Earnings: What's in the Cards?,https://www.zacks.com/stock/news/2128877/incyte-incy-to-report-q2-earnings-whats-in-the-cards,2023-07-27 14:20:00,Incyte's (INCY) second-quarter 2023 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.,INCY,0.500227,0.263056,Somewhat-Bullish
"Biotech Stock Roundup: BIIB, GSK's Q2 Earnings, KOD Faces Setback & More",https://www.zacks.com/stock/news/2128013/biotech-stock-roundup-biib-gsks-q2-earnings-kod-faces-setback-more,2023-07-26 14:08:00,Earnings updates from Biogen (BIIB) and GSK (GSK) are in focus in the biotech sector.,INCY,0.038969,0.014869,Neutral
"Earnings Preview: Castle Biosciences, Inc.  ( CSTL )  Q2 Earnings Expected to Decline",https://www.zacks.com/stock/news/2127963/earnings-preview-castle-biosciences-inc-cstl-q2-earnings-expected-to-decline,2023-07-26 14:02:01,"Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",INCY,0.172097,-0.025383,Neutral
"Cathie Wood Buys Spotify, Iridium Shares, Sells Tesla, Coinbase Stock - Iridium Comms  ( NASDAQ:IRDM ) , ARK Next Generation Internet ETF  ( ARCA:ARKW ) , Tesla  ( NASDAQ:TSLA ) , Spotify Technology  ( NYSE:SPOT ) , ARK Autonomous Technology & Robotics ETF  ( BATS:ARKQ ) , Incyte  ( NASDAQ:INCY ) , AAR  ( NYSE:AIR ) , Cameco  ( NYSE:CCJ ) , Accolade  ( NASDAQ:ACCD ) , Coinbase Glb  ( NASDAQ:COIN ) , Kratos Defense & Security  ( NASDAQ:KTOS ) ",https://www.benzinga.com/markets/equities/23/07/33382620/cathie-woods-ark-invest-buys-spotify-iridium-shares-trims-tesla-coinbase-holdings,2023-07-26 02:39:46,"On Tuesday, Cathie Wood-led Ark Invest made a series of trades, with the most notable being the purchase of shares in Spotify Technology SA SPOT and Iridium Communications Inc IRDM, and the sale of shares in Coinbase Global Inc COIN and Tesla Inc TSLA.",INCY,0.211191,0.378306,Bullish
Earnings Preview: Incyte  ( INCY )  Q2 Earnings Expected to Decline,https://www.zacks.com/stock/news/2126967/earnings-preview-incyte-incy-q2-earnings-expected-to-decline,2023-07-25 14:01:32,Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,INCY,0.299478,0.008925,Neutral
"Kiniksa Pharmaceuticals, Ltd.  ( KNSA )  Reports Q2 Loss, Tops Revenue Estimates",https://www.zacks.com/stock/news/2126742/kiniksa-pharmaceuticals-ltd-knsa-reports-q2-loss-tops-revenue-estimates,2023-07-25 12:45:07,"Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 87.50% and 36.58%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?",INCY,0.136113,0.0,Neutral
"Syndax-Incyte Partnered Chronic Graft-Versus-Host Disease Achieves Primary Endpoint In Pivotal Trial, FDA Submission Planned By 2023 End - Incyte  ( NASDAQ:INCY ) , Syndax Pharmaceuticals  ( NASDAQ:SNDX ) ",https://www.benzinga.com/general/biotech/23/07/33346449/syndax-incyte-partnered-chronic-graft-versus-host-disease-achieves-primary-endpoint-in-pivotal-tr,2023-07-24 15:10:31,"Syndax Pharmaceuticals SNDX and Incyte Corporation INCY announced topline data from the AGAVE-201 trial of axatilimab, in adult and pediatric patients with chronic graft-versus-host disease ( GVHD ) following two or more prior lines of therapy.",INCY,0.573213,0.128793,Neutral
"'I Don't Want You To Touch That': Cramer Rejects Stock Down 32% Over Past Month, Prefers Tesla - Alexandria Real Estate  ( NYSE:ARE ) , AST SpaceMobile  ( NASDAQ:ASTS ) ",https://www.benzinga.com/trading-ideas/long-ideas/23/07/33278944/i-dont-want-you-to-touch-that-cramer-rejects-stock-down-32-over-past-month-prefers-tesla,2023-07-19 12:42:55,"On CNBC's ""Mad Money Lightning Round,"" Jim Cramer said Alexandria Real Estate Equities, Inc. ARE is ""one of the better real estate investment trusts, but I would rather see you in Federal Realty Investment Trust FRT, which I think does a very better job, and I think Don Wood is the man.""",INCY,0.352223,0.290036,Somewhat-Bullish
5 Beaten-Down Healthcare Stocks With Potential for a Rebound,https://www.barrons.com/articles/bargain-healthcare-stocks-rebound-f2c744a9,2023-07-19 07:31:00,"Investors have fled healthcare stocks this year, ducking out of a trade that seemed a smart defensive play last year, as market conditions have changed. Fear of a recession has eased and interest rates have climbed, making the pull of big pharma's steady dividends less potent.",INCY,0.154951,0.0,Neutral
Incyte's  ( INCY )  Opzelura Meets Goal in Phase III Pediatric Study,https://www.zacks.com/stock/news/2119999/incytes-incy-opzelura-meets-goal-in-phase-iii-pediatric-study,2023-07-12 14:52:00,Incyte's (INCY) Opzelura (ruxolitinib cream) meets the primary endpoint in a phase III study in children with atopic dermatitis.,INCY,0.414559,0.512685,Bullish
Incyte Skin Disease Drug Meets Primary Goal In Late-Stage Study In Children - Incyte  ( NASDAQ:INCY ) ,https://www.benzinga.com/general/biotech/23/07/33196093/incyte-skin-disease-drug-meets-primary-goal-in-late-stage-study-in-children,2023-07-12 12:23:26,Incyte Corporation INCY released topline results from its Phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream ( Opzelura ) in children with atopic dermatitis ( AD ) .,INCY,0.47379,0.304508,Somewhat-Bullish
Incyte skin disease drug for children meets main goal in late-stage study,https://www.reuters.com/business/healthcare-pharmaceuticals/incyte-skin-disease-drug-children-meets-main-goal-late-stage-study-2023-07-11/,2023-07-11 20:23:00,July 11 ( Reuters ) - Incyte Corp ( INCY.O ) said on Tuesday its experimental drug to treat a skin condition in children between the age of two to twelve met the primary goal in a late-stage study.,INCY,0.47672,0.231974,Somewhat-Bullish
Syndax Pharmaceuticals Set for Potential Breakthrough with Revumenib: Analyst Calls It 'Potentially Best-In-Class' In Competitive Landscape - Syndax Pharmaceuticals  ( NASDAQ:SNDX ) ,https://www.benzinga.com/general/biotech/23/07/33188619/syndax-pharmaceuticals-set-for-potential-breakthrough-with-revumenib-analyst-calls-it-potentially,2023-07-11 19:43:04,"Guggenheim Partners initiated coverage on Syndax Pharmaceuticals Inc SNDX with a BUY rating and a price target of $40. SNDX's lead asset and principal value driver is revumenib, an inhibitor of menin in development for a genetically defined subset of leukemias that currently have no FDA-approved ...",INCY,0.331765,0.186787,Somewhat-Bullish
GMAB: Invest in These 3 High-Growth Biotech Stocks,https://stocknews.com/news/gmab-incy-lvtx-invest-in-these-3-high-growth-biotech-stocks/,2023-07-10 15:50:53,"The biotech sector is rapidly expanding thanks to solid demand, technological improvements, and government incentives. Therefore, quality biotech stocks Genmab A/S ( GMAB ) , Incyte Corporation ( INCY ) , and LAVA Therapeutics N.V. ( LVTX ) , which look poised to grow, could be wise additions to ...",INCY,0.234307,0.157159,Somewhat-Bullish
"Biotech Stock Roundup: BMRN's Gene Therapy Gets Approval, SGTX Up on Buyout by LLY",https://www.zacks.com/stock/news/2117618/biotech-stock-roundup-bmrns-gene-therapy-gets-approval-sgtx-up-on-buyout-by-lly,2023-07-06 14:36:00,Regulatory and acquisition updates from BioMarin (BMRN) and Sigilon (SGTX) are in focus in the biotech sector.,INCY,0.043186,0.095499,Neutral
Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight,https://www.prnewswire.com/news-releases/bispecific-antibody-clinical-trial-pipeline-appears-robust-with-250-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-301868673.html,2023-07-03 21:01:00,Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the ... PR ...,INCY,0.020404,-0.005463,Neutral
Short Volatility Alert: Incyte Corporation - Incyte  ( NASDAQ:INCY ) ,https://www.benzinga.com/23/06/33078349/short-volatility-alert-incyte-corporation,2023-06-30 13:41:01,"On Thursday, shares of Incyte Corporation INCY experienced volatile short activity. After the activity, the stock price went up +1.48% to $61.85. The overall sentiment for INCY has been Bearish. The signal from the volatility alert is trending Bullish. Therefore, the recommendation is to Strong ...",INCY,0.350564,-0.211763,Somewhat-Bearish
INCY: Are These 3 Biotech Stocks Good Buys?,https://stocknews.com/news/incy-cort-trda-are-these-3-biotech-stocks-good-buys/,2023-06-27 11:56:29,"The biotech industry is well-positioned to thrive, owing to inelastic demand, rapid developments, and government initiatives. So, quality biotech stocks Incyte Corporation ( INCY ) , Corcept Therapeutics Incorporated ( CORT ) , and Entrada Therapeutics, Inc. ( TRDA ) could be worth buying.",INCY,0.326824,0.303395,Somewhat-Bullish
2 Low-Priced Stocks That Could Make You Richer,https://www.fool.com/investing/2023/06/26/2-low-priced-stocks-that-could-make-you-richer/,2023-06-26 14:15:00,These two low-priced healthcare stocks could skyrocket within the next 12 months.,INCY,0.051774,0.066592,Neutral
Recently-Appointed Independent Directors of Alkermes Issue Open Letter to Shareholders,https://www.prnewswire.com/news-releases/recently-appointed-independent-directors-of-alkermes-issue-open-letter-to-shareholders-301862757.html,2023-06-26 11:00:00,"Recommend Shareholders Vote ""For"" Alkermes' Seven Director Nominees On Company's Proxy Card",INCY,0.018995,0.0,Neutral
Recently-Appointed Independent Directors of Alkermes Issue Open Letter to Shareholders - Alkermes  ( NASDAQ:ALKS ) ,https://www.benzinga.com/pressreleases/23/06/n33002604/recently-appointed-independent-directors-of-alkermes-issue-open-letter-to-shareholders,2023-06-26 11:00:00,"Recommend Shareholders Vote ""For"" Alkermes' Seven Director Nominees On Company's White Proxy Card",INCY,0.018439,0.125498,Neutral
"Alopecia Areata Market to Show Positive Growth at a CAGR of 26.3% During the Study Period  ( 2019-2032 ) , Estimates DelveInsight",https://www.prnewswire.com/news-releases/alopecia-areata-market-to-show-positive-growth-at-a-cagr-of-26-3-during-the-study-period-20192032-estimates-delveinsight-301853907.html,2023-06-19 20:00:00,"Alopecia Areata Market to Show Positive Growth at a CAGR of 26.3% During the Study Period ( 2019-2032 ) , Estimates ... PR ...",INCY,0.026474,0.037854,Neutral
AVITA Medical Announces FDA Approval of RECELL for Skin Repigmentation in Vitiligo Patients,https://www.globenewswire.com/news-release/2023/06/16/2689906/0/en/AVITA-Medical-Announces-FDA-Approval-of-RECELL-for-Skin-Repigmentation-in-Vitiligo-Patients.html,2023-06-16 18:47:00,"VALENCIA, Calif. and MELBOURNE, Australia, June 16, 2023 ( GLOBE NEWSWIRE ) -- AVITA Medical, Inc. ( NASDAQ: RCEL, ASX: AVH ) , a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today ...",INCY,0.034332,0.0,Neutral
New Strong Sell Stocks for June 16th,https://www.zacks.com/stock/news/2109261/new-strong-sell-stocks-for-june-16th,2023-06-16 11:08:00,"ARCH, EQBK and INCY have been added to the Zacks Rank #5 (Strong Sell) List on June 16, 2023.",INCY,0.608634,-0.229942,Somewhat-Bearish
Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors - Alkermes  ( NASDAQ:ALKS ) ,https://www.benzinga.com/pressreleases/23/06/n32831446/alkermes-issues-letter-to-shareholders-highlighting-skills-and-experience-of-refreshed-board-of-di,2023-06-13 11:00:00,"Sarissa's Proposed Candidates Would Not Bring New Skills to the Board Recommends Shareholders Vote ""FOR"" Alkermes' Director Nominees on Company's WHITE Proxy Card",INCY,0.019102,0.0,Neutral
Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board,https://www.globenewswire.com/news-release/2023/06/12/2686674/0/en/Galapagos-appoints-Dr-Susanne-Schaffert-as-non-executive-independent-Director-to-its-Board.html,2023-06-12 20:01:00,"Mechelen, Belgium. 12 June 2023, 22:01 CET. Galapagos NV ( Euronext & NASDAQ: GLPG ) today announced that during its meeting of 12 June 2023, the Board of Directors co-opted Dr. Susanne Schaffert as non-executive independent Director. Dr. Schaffert replaces Dr. Rajesh Parekh who stepped down on ...",INCY,0.100308,-0.087144,Neutral
Innovent Announces Phase 1 Clinical Data of IBI322  ( CD47/PD-L1 Bispecific Antibody )  in the Treatment of Anti-PD- ( L ) 1-resistant Classic Hodgkin Lymphoma Patients at the EHA 2023 Annual Meeting,https://www.prnewswire.com/news-releases/innovent-announces-phase-1-clinical-data-of-ibi322-cd47pd-l1-bispecific-antibody-in-the-treatment-of-anti-pd-l1-resistant-classic-hodgkin-lymphoma-patients-at-the-eha-2023-annual-meeting-301847812.html,2023-06-12 00:00:00,Innovent Announces Phase 1 Clinical Data of IBI322 ( CD47/PD-L1 ... PR ...,INCY,0.088255,0.108073,Neutral
Alkermes Publishes Investor Presentation Detailing Company's Transformation and Value Creation,https://www.prnewswire.com/news-releases/alkermes-publishes-investor-presentation-detailing-companys-transformation-and-value-creation-301846055.html,2023-06-08 11:00:00,Alkermes Publishes Investor Presentation Detailing Company's ... PR ...,INCY,0.021778,0.125225,Neutral
Innovent Presents Phase 1b Clinical Data of IBI110  ( Anti-LAG-3 Monoclonal Antibody )  at the 2023 ASCO Annual Meeting,https://www.prnewswire.com/news-releases/innovent-presents-phase-1b-clinical-data-of-ibi110-anti-lag-3-monoclonal-antibody-at-the-2023-asco-annual-meeting-301841856.html,2023-06-05 00:00:00,Innovent Presents Phase 1b Clinical Data of IBI110 ( Anti-LAG-3 ... PR ...,INCY,0.075794,0.105167,Neutral
Innovent Updates Phase 1b Data of IBI939  ( Anti-TIGIT Monoclonal Antibody )  Combined with Sintilimab in Previously Untreated PD-L1-selected NSCLC at the 2023 ASCO Annual Meeting,https://www.prnewswire.com/apac/news-releases/innovent-updates-phase-1b-data-of-ibi939-anti-tigit-monoclonal-antibody-combined-with-sintilimab-in-previously-untreated-pd-l1-selected-nsclc-at-the-2023-asco-annual-meeting-301841842.html,2023-06-04 00:36:00,Innovent Updates Phase 1b Data of IBI939 ( Anti-TIGIT Monoclonal ... PR ...,INCY,0.095138,0.09527,Neutral
Innovent Updates Phase 1b Data of IBI939  ( Anti-TIGIT Monoclonal Antibody )  Combined with Sintilimab in Previously Untreated PD-L1-selected NSCLC at the 2023 ASCO Annual Meeting,https://www.prnewswire.com/news-releases/innovent-updates-phase-1b-data-of-ibi939-anti-tigit-monoclonal-antibody-combined-with-sintilimab-in-previously-untreated-pd-l1-selected-nsclc-at-the-2023-asco-annual-meeting-301841804.html,2023-06-04 00:00:00,Innovent Updates Phase 1b Data of IBI939 ( Anti-TIGIT Monoclonal ... PR ...,INCY,0.095138,0.09527,Neutral
Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST,https://www.prnewswire.com/news-releases/innovent-announces-the-second-breakthrough-therapy-designation-by-nmpa-for-olverembatinib-for-the-treatment-of-patients-with-sdh-deficient-gist-301841691.html,2023-06-02 23:59:00,Innovent Announces the Second Breakthrough Therapy Designation ... PR ...,INCY,0.070725,0.104313,Neutral
"Biotech Stock Roundup: MRTX Falls on Study Failure, LXRX Drug Wins Approval & More",https://www.zacks.com/stock/news/2102778/biotech-stock-roundup-mrtx-falls-on-study-failure-lxrx-drug-wins-approval-more,2023-06-01 15:35:00,Regulatory and pipeline updates from Mirati (MRTX) and Lexicon (LXRX) are in focus in the biotech sector.,INCY,0.049424,-0.115734,Neutral
Alkermes Files Definitive Proxy Statement and Issues Letter to Shareholders Detailing Business Execution That Has Driven Strong Performance and Delivered Shareholder Value,https://www.prnewswire.com/news-releases/alkermes-files-definitive-proxy-statement-and-issues-letter-to-shareholders-detailing-business-execution-that-has-driven-strong-performance-and-delivered-shareholder-value-301835124.html,2023-05-25 20:15:00,Alkermes Files Definitive Proxy Statement and Issues Letter to ... PR ...,INCY,0.008968,0.0,Neutral
Alkermes Files Definitive Proxy Statement and Issues Letter to Shareholders Detailing Business Execution That Has Driven Strong Performance and Delivered Shareholder Value - Alkermes  ( NASDAQ:ALKS ) ,https://www.benzinga.com/pressreleases/23/05/n32584139/alkermes-files-definitive-proxy-statement-and-issues-letter-to-shareholders-detailing-business-exe,2023-05-25 20:15:00,"Company Has Outperformed Peers and Relevant Indices Since Unveiling its December 2020 Value Enhancement Plan 70% of Board's Independent Directors Have Been Appointed Over the Last Four Years, Including Four Directors Designated or Supported by Shareholders",INCY,0.008935,0.0,Neutral
BMRN: 3 Biotech Stocks Poised to Skyrocket,https://stocknews.com/news/bmrn-incy-inva-mor-3-biotech-stocks-poised-to-skyrocket/,2023-05-15 16:45:06,"Biotechnology advancements have created new ways of treating and preventing major life-threatening diseases. With accelerating advancement and increased tech integration in healthcare, renowned companies BioMarin Pharmaceutical Inc. ( BMRN ) , Incyte Corporation ( INCY ) , and Innoviva, Inc. ( ...",INCY,0.287762,0.194709,Somewhat-Bullish
Innovent Receives NMPA Breakthrough Designation for IBI351  ( KRASG12C Inhibitor )  as Monotherapy for Previously Treated Advanced Colorectal Carcinoma,https://www.prnewswire.com/apac/news-releases/innovent-receives-nmpa-breakthrough-designation-for-ibi351-krasg12c-inhibitor-as-monotherapy-for-previously-treated-advanced-colorectal-carcinoma-301824027.html,2023-05-15 00:00:00,Innovent Receives NMPA Breakthrough Designation for IBI351 ... PR ...,INCY,0.092807,0.1094,Neutral
Innovent Receives NMPA Breakthrough Designation for IBI351  ( KRASG12C Inhibitor )  as Monotherapy for Previously Treated Advanced Colorectal Carcinoma,https://www.prnewswire.com/news-releases/innovent-receives-nmpa-breakthrough-designation-for-ibi351-krasg12c-inhibitor-as-monotherapy-for-previously-treated-advanced-colorectal-carcinoma-301824026.html,2023-05-15 00:00:00,Innovent Receives NMPA Breakthrough Designation for IBI351 ... PR ...,INCY,0.092807,0.1094,Neutral
MacroGenics  ( MGNX )  Q1 2023 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/05/10/macrogenics-mgnx-q1-2023-earnings-call-transcript/,2023-05-10 04:30:40,"MGNX earnings call for the period ending March 31, 2023.",INCY,0.056518,0.118986,Neutral
Syndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update,https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-first-quarter-2023-financial-results-and-provides-clinical-and-business-update-301818643.html,2023-05-08 20:05:00,Syndax Pharmaceuticals Reports First Quarter 2023 Financial ... PR ...,INCY,0.056407,0.0,Neutral
Innovent Announces First Participant Dosed in Phase 3 Study  ( RESTORE )  of IBI311  ( Anti-IGF-1R Monoclonal Antibody )  in Patients with Thyroid Eye Disease,https://www.prnewswire.com/apac/news-releases/innovent-announces-first-participant-dosed-in-phase-3-study-restore-of-ibi311-anti-igf-1r-monoclonal-antibody-in-patients-with-thyroid-eye-disease-301817785.html,2023-05-08 00:00:00,Innovent Announces First Participant Dosed in Phase 3 Study ... PR ...,INCY,0.070105,0.104223,Neutral
Innovent Announces First Participant Dosed in Phase 3 Study  ( RESTORE )  of IBI311  ( Anti-IGF-1R Monoclonal Antibody )  in Patients with Thyroid Eye Disease,https://www.prnewswire.com/news-releases/innovent-announces-first-participant-dosed-in-phase-3-study-restore-of-ibi311-anti-igf-1r-monoclonal-antibody-in-patients-with-thyroid-eye-disease-301817782.html,2023-05-08 00:00:00,Innovent Announces First Participant Dosed in Phase 3 Study ... PR ...,INCY,0.070105,0.104223,Neutral
Innovent Updates the Results from the ORIENT-31 Study of Sintilimab Plus Chemotherapy With or Without Bevacizumab in Patients with EGFR-TKI failed EGFR-mutated Non-Squamous Non-Small Cell Lung Cancer in the Lancet Respiratory Medicine,https://www.prnewswire.com/apac/news-releases/innovent-updates-the-results-from-the-orient-31-study-of-sintilimab-plus-chemotherapy-with-or-without-bevacizumab-in-patients-with-egfr-tki-failed-egfr-mutated-non-squamous-non-small-cell-lung-cancer-in-the-lancet-respiratory-medi-301817768.html,2023-05-08 00:00:00,Innovent Updates the Results from the ORIENT-31 Study of ... PR ...,INCY,0.048165,0.102777,Neutral
Market Rally Finishes Strong As Banks Slash Losses: Weekly Review,https://www.investors.com/news/market-rally-finishes-strong-regional-banks-fed-rate-hike-jobs-report-apple-in-focus/,2023-05-05 17:16:00,"Market Rally Finishes Strong. Regional Banks, Fed Rate Hike, Jobs ... Investor's Business Daily ...",INCY,0.037021,-0.177177,Somewhat-Bearish
Merus Announces Financial Results for the First Quarter 2023 and Provides Business Update,https://www.globenewswire.com/news-release/2023/05/04/2662114/37568/en/Merus-Announces-Financial-Results-for-the-First-Quarter-2023-and-Provides-Business-Update.html,2023-05-04 20:25:00,- Petosemtamab clinical update presented at the American Association of Cancer Research ( AACR ) Annual Meeting 2023- Petosemtamab end-of-phase meeting with U.S. Food & Drug Administration provides clarity to potential registration path in head and neck squamous cell carcinoma ( HNSCC ) - ...,INCY,0.091277,0.036098,Neutral
"Incyte  ( NASDAQ:INCY )  Lowered to ""Buy"" at StockNews.com",https://www.defenseworld.net/2023/05/04/incyte-nasdaqincy-lowered-to-buy-at-stocknews-com.html,2023-05-04 08:48:50,StockNews.com lowered shares of Incyte ( NASDAQ:INCY - Get Rating ) from a strong-buy rating to a buy rating in a report published on Wednesday. INCY has been the subject of several other research reports. Mizuho lowered their target price on shares of Incyte from $95.00 to $82.00 in a research ...,INCY,0.939207,0.411673,Bullish
"Incyte  ( INCY )  Q1 Earnings Miss Estimates, Revenues Up Y/Y",https://www.zacks.com/stock/news/2088492/incyte-incy-q1-earnings-miss-estimates-revenues-up-yy,2023-05-02 19:18:00,Incyte's (INCY) first-quarter 2023 earnings and revenues miss estimates due to higher patient deductibles and inventory challenges.,INCY,0.568148,0.065279,Neutral
Seasonality Hacked Away At Incyte's First-Quarter Sales,https://www.investors.com/news/technology/incyte-stock-crumbles-as-seasonality-hacks-at-first-quarter-sales/,2023-05-02 17:32:00,Incyte Stock Crumbles As Seasonality Hacks At First-Quarter Sales ... Investor's Business Daily ...,INCY,0.468029,-0.077309,Neutral
Why Incyte  ( INCY )  Shares Are Falling Today - Incyte  ( NASDAQ:INCY ) ,https://www.benzinga.com/general/biotech/23/05/32162157/why-incyte-shares-are-falling-today,2023-05-02 16:21:18,"Incyte Corporation's INCY shares are plunging today after the company missed Wall Street's expectations. The company's Q1 adjusted EPS reached $0.37, compared to $0.55 posted a year ago. Analysts had estimated $0.75. Q1 total revenues increased by 11% Y/Y to $808.67 million, missing the consensus ...",INCY,0.483434,0.22634,Somewhat-Bullish
Incyte misses quarterly estimates on weak sales of key drugs,https://www.reuters.com/business/healthcare-pharmaceuticals/incyte-misses-quarterly-estimates-weak-sales-key-drugs-2023-05-02/,2023-05-02 13:25:00,May 2 ( Reuters ) - Incyte Corp ( INCY.O ) on Tuesday reported first-quarter profit and revenue below Wall Street estimates as sales of two of its key drugs were hit by lower medical insurance coverage.,INCY,0.524949,-0.141294,Neutral
Incyte  ( INCY )  Q1 Earnings and Revenues Miss Estimates,https://www.zacks.com/stock/news/2087902/incyte-incy-q1-earnings-and-revenues-miss-estimates,2023-05-02 12:15:14,"Incyte (INCY) delivered earnings and revenue surprises of -56.47% and 7.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?",INCY,0.402403,0.127737,Neutral
"The Zacks Analyst Blog Highlights Fomento Economico Mexicano, NextEra Energy, Charter Communications, General Electric and Incyte",https://www.zacks.com/stock/news/2086655/the-zacks-analyst-blog-highlights-fomento-economico-mexicano-nextera-energy-charter-communications-general-electric-and-incyte,2023-04-28 09:00:00,"Fomento Economico Mexicano, NextEra Energy, Charter Communications, General Electric and Incyte are included in this Analyst Blog.",INCY,0.682689,0.0,Neutral
"Eli Lilly  ( LLY )  Q1 Earnings Miss, Sales Beat, '23 View Raised",https://www.zacks.com/stock/news/2086376/eli-lilly-lly-q1-earnings-miss-sales-beat-23-view-raised,2023-04-27 18:25:00,"Eli Lilly (LLY) reports mixed results for the first quarter of 2023, missing estimates for earnings while beating the same for revenues. Management raises the 2023 outlook.",INCY,0.029914,-0.000933,Neutral
"Top Analyst Reports for Fomento Economico Mexicano, NextEra Energy & Charter Communications",https://www.zacks.com/research-daily/2086066/top-analyst-reports-for-fomento-economico-mexicano-nextera-energy-charter-communications,2023-04-27 16:56:00,"Today's Research Daily features new research reports on 16 major stocks, including Fomento Economico Mexicano, S.A.B. de C.V. (FMX), NextEra Energy, Inc. (NEE) and Charter Communications, Inc. (CHTR).",INCY,0.122894,0.124508,Neutral
"CURE Media Group announces Abbey Kaler, MS, APRN, FNP-C, CMSRN, as winner of 2023 Extraordinary Healer® Award",https://www.benzinga.com/pressreleases/23/04/g32047083/cure-media-group-announces-abbey-kaler-ms-aprn-fnp-c-cmsrn-as-winner-of-2023-extraordinary-healer-,2023-04-27 13:40:15,Kaler was recognized for her remarkable contributions in oncology care,INCY,0.262052,0.362553,Bullish
"The Zacks Analyst Blog Highlights Biogen, Incyte, Morphic Therapeutic and bluebird bio",https://www.zacks.com/stock/news/2085613/the-zacks-analyst-blog-highlights-biogen-incyte-morphic-therapeutic-and-bluebird-bio,2023-04-27 10:10:00,"Biogen, Incyte, Morphic Therapeutic and bluebird bio are included in this Analyst Blog.",INCY,0.152499,0.123914,Neutral
Will Jakafi Sales Drive a Beat For Incyte  ( INCY )  Q1 Earnings?,https://www.zacks.com/stock/news/2085256/will-jakafi-sales-drive-a-beat-for-incyte-incy-q1-earnings,2023-04-26 15:03:00,Incyte's (INCY) first-quarter 2023 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.,INCY,0.666827,0.288156,Somewhat-Bullish
Allogene Therapeutics  ( ALLO )  Expected to Beat Earnings Estimates: Should You Buy?,https://www.zacks.com/stock/news/2085024/allogene-therapeutics-allo-expected-to-beat-earnings-estimates-should-you-buy,2023-04-26 14:02:26,Allogene Therapeutics (ALLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,INCY,0.174903,0.047487,Neutral
"Biotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates",https://www.zacks.com/stock/news/2084747/biotech-stock-roundup-biibs-q1-results-arwr-up-on-data-incy-blue-offer-updates,2023-04-26 11:06:00,Earnings and pipeline updates from Biogen (BIIB) and Arrowhead (ARWR) are they key highlights of the biotech sector.,INCY,0.12003,0.149818,Neutral
Incyte  ( INCY )  Earnings Expected to Grow: What to Know Ahead of Next Week's Release,https://www.zacks.com/stock/news/2084210/incyte-incy-earnings-expected-to-grow-what-to-know-ahead-of-next-weeks-release,2023-04-25 14:01:27,Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,INCY,0.261117,0.216037,Somewhat-Bullish
Incyte  ( NASDAQ:INCY )  Upgraded to Strong-Buy by StockNews.com,https://www.defenseworld.net/2023/04/25/incyte-nasdaqincy-upgraded-to-strong-buy-by-stocknews-com.html,2023-04-25 08:40:48,StockNews.com upgraded shares of Incyte ( NASDAQ:INCY - Get Rating ) from a buy rating to a strong-buy rating in a research report report published on Monday morning. INCY has been the subject of several other research reports.,INCY,0.766922,0.353665,Bullish
"Novartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance",https://www.globenewswire.com/news-release/2023/04/25/2653492/0/en/Novartis-delivers-strong-sales-growth-robust-margin-expansion-and-major-innovation-milestones-Raises-FY-guidance.html,2023-04-25 05:00:00,Ad hoc announcement pursuant to Art. 53 LR ...,INCY,0.015512,0.0,Neutral
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Incyte Corporation - INCY,https://www.benzinga.com/pressreleases/23/04/g31965986/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-incyte-corporat,2023-04-24 18:19:36,"NEW YORK, April 24, 2023 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Incyte Corporation ( ""Incyte"" or the ""Company"" ) INCY. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.",INCY,0.689652,0.060545,Neutral
What's in Store for Molina Healthcare  ( MOH )  in Q1 Earnings?,https://www.zacks.com/stock/news/2083610/whats-in-store-for-molina-healthcare-moh-in-q1-earnings,2023-04-24 16:01:00,"Molina Healthcare's (MOH) Q1 results are likely to have benefited from the strong performance of its Medicaid and Medicare businesses, partly offset by rising operating costs.",INCY,0.095899,0.09985,Neutral
What To Expect When Incyte Reports Q1 Earnings In Almost Two Weeks - Incyte  ( NASDAQ:INCY ) ,https://www.benzinga.com/analyst-ratings/analyst-color/23/04/31939846/what-to-expect-when-incyte-reports-q1-earnings-in-almost-two-weeks,2023-04-21 19:06:37,"Incyte Corporation INCY will report Q1 FY23 results on May 2. Investor focus remains on the Opzelura launch, which has faced some hiccups over the first 18 months of launch and began to gain traction toward the end of 2022.",INCY,0.543935,-0.149544,Neutral
Incyte  ( INCY )  Opzelura Gets EC Nod for Non-Segmental Vitiligo,https://www.zacks.com/stock/news/2082973/incyte-incy-opzelura-gets-ec-nod-for-non-segmental-vitiligo,2023-04-21 16:44:00,Incyte (INCY) gets EC approval for Opzelura (cream formulation of ruxolitinib) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.,INCY,0.455978,0.116745,Neutral
Innovent Releases Final Analysis Results of ORIENT-15: the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma at the AACR Annual Meeting 2023,https://www.prnewswire.com/apac/news-releases/innovent-releases-final-analysis-results-of-orient-15-the-phase-3-study-of-sintilimab-plus-chemotherapy-for-the-first-line-treatment-of-esophageal-squamous-cell-carcinoma-at-the-aacr-annual-meeting-2023-301798436.html,2023-04-17 00:33:00,Innovent Releases Final Analysis Results of ORIENT-15: the Phase ... PR ...,INCY,0.020958,0.139175,Neutral
Innovent Releases Final Analysis Results of ORIENT-15: the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma at the AACR Annual Meeting 2023,https://www.prnewswire.com/news-releases/innovent-releases-final-analysis-results-of-orient-15-the-phase-3-study-of-sintilimab-plus-chemotherapy-for-the-first-line-treatment-of-esophageal-squamous-cell-carcinoma-at-the-aacr-annual-meeting-2023-301798427.html,2023-04-17 00:20:00,Innovent Releases Final Analysis Results of ORIENT-15: the Phase ... PR ...,INCY,0.020958,0.139175,Neutral
How The Texas Abortion Ruling Could Destroy Biotech Stocks,https://www.investors.com/news/technology/biotech-stocks-how-the-texas-abortion-ruling-could-be-their-undoing/,2023-04-14 12:15:00,"A federal judge's decision in Texas to outlaw a decades-old abortion drug undermines the foundation of all biotech stocks, warns a group of nearly 600 health care executives and experts. Chiefs of big medical names like Pfizer ( PFE ) , Biogen ( BIIB ) and Incyte ( INCY ) are uniting to oppose ...",INCY,0.074926,0.020285,Neutral
Ominous Death Cross Forms On Incyte's Chart - Incyte  ( NASDAQ:INCY ) ,https://www.benzinga.com/markets/23/04/31790214/ominous-death-cross-forms-on-incytes-chart,2023-04-13 14:47:31,"If history is any guide, there may be trouble ahead for shares of Incyte INCY. A so-called ""death cross"" has formed on its chart and, not surprisingly, this could be bearish for the stock. What To Know: Many traders use moving average crossover systems to make their decisions.",INCY,0.570165,-0.461617,Bearish
StockNews.com Downgrades Incyte  ( NASDAQ:INCY )  to Buy,https://www.defenseworld.net/2023/04/12/stocknews-com-downgrades-incyte-nasdaqincy-to-buy.html,2023-04-12 05:30:48,"Incyte ( NASDAQ:INCY - Get Rating ) was downgraded by investment analysts at StockNews.com from a ""strong-buy"" rating to a ""buy"" rating in a report issued on Wednesday. A number of other equities research analysts also recently weighed in on the stock.",INCY,0.793719,0.392535,Bullish
S&P 500: Two Chip Plays Are Monday's Big Winners,https://www.investors.com/news/sp-500-stocks-micron-charles-schwab-among-top-performers-monday/,2023-04-10 20:28:00,"S&P 500 Stocks: Micron, Charles Schwab Among Top Performers ... Investor's Business Daily ...",INCY,0.355588,-0.273438,Somewhat-Bearish
"Valero Energy To Rally 32%? Here Are 10 Other Analyst Forecasts For Monday - Clene  ( NASDAQ:CLNN ) , Boeing  ( NYSE:BA ) ",https://www.benzinga.com/news/23/04/31724728/valero-energy-to-rally-32-here-are-10-other-analyst-forecasts-for-monday,2023-04-10 12:32:13,Credit Suisse boosted the price target for The Boeing Company BA from $200 to $220. Credit Suisse analyst Scott Deuschle maintained a Neutral rating on the stock. Boeing shares fell 0.4% to $210.60 in pre-market trading. Raymond James boosted the price target for Valero Energy Corporation VLO ...,INCY,0.276909,0.004345,Neutral
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Incyte Corporation - INCY,https://www.benzinga.com/pressreleases/23/04/g31719522/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-incyte-corporat,2023-04-09 06:38:18,"NEW YORK, April 09, 2023 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Incyte Corporation ( ""Incyte"" or the ""Company"" ) INCY. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.",INCY,0.689652,0.060545,Neutral
Here's How Much a $1000 Investment in Eli Lilly Made 10 Years Ago Would Be Worth Today,https://www.zacks.com/stock/news/2075911/heres-how-much-a-1000-investment-in-eli-lilly-made-10-years-ago-would-be-worth-today,2023-04-07 12:30:04,"Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.",INCY,0.053992,0.034985,Neutral
Is Invesco Dynamic Biotechnology & Genome ETF  ( PBE )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2075894/is-invesco-dynamic-biotechnology-genome-etf-pbe-a-strong-etf-right-now,2023-04-07 10:20:11,Smart Beta ETF report for ...,INCY,0.113866,0.060813,Neutral
MorphoSys Up on Finishing Early Enrolment in Myelofibrosis Study,https://www.zacks.com/stock/news/2075725/morphosys-up-on-finishing-early-enrolment-in-myelofibrosis-study,2023-04-06 16:19:00,"As MorphoSys (MOR) completes enrolment before schedule in a late-stage study evaluating therapy in myelofibrosis patients, the top-line data from this study is now expected early.",INCY,0.318897,0.183412,Somewhat-Bullish
Incyte  ( INCY )  Down 9.6% so Far in 2023 on Recent Setbacks,https://www.zacks.com/stock/news/2075137/incyte-incy-down-96-so-far-in-2023-on-recent-setbacks,2023-04-05 20:48:00,Incyte (INCY) shares are down 9.6% in the year so far on pipeline setbacks.,INCY,0.431765,0.046384,Neutral
"Zevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph.D., to Board of Directors",https://www.globenewswire.com/news-release/2023/03/30/2637531/16626/en/Zevra-Therapeutics-Appoints-Biopharma-Veteran-Wendy-Dixon-Ph-D-to-Board-of-Directors.html,2023-03-30 11:30:00,"CELEBRATION, Fla., March 30, 2023 ( GLOBE NEWSWIRE ) -- Zevra Therapeutics ( NasdaqGS: ZVRA ) ( ""Zevra"" or the ""Company"" and formerly KemPharm, Inc. ) , a rare disease therapeutics company, today announced that it has appointed Wendy L. Dixon, Ph.D., to the Company's Board of Directors ( the ...",INCY,0.033098,0.0,Neutral
"Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback",https://www.zacks.com/stock/news/2072025/biotech-stock-roundup-vktx-bmea-itci-soar-on-study-data-incy-faces-setback,2023-03-29 15:24:00,Pipelines updates from Viking Therapeutics (VKTX) and Intra-Cellular (ITCI) are the key highlights for the biotech sector.,INCY,0.203786,0.016231,Neutral
EXEL: 3 Biotech Stocks Losing Momentum as March Ends,https://stocknews.com/news/exel-mgnx-pbyi-incy-3-biotech-stocks-losing-momentum-as-march-ends/,2023-03-29 14:17:36,"Increasing investments in innovation and scientific research has propelled the biotech industry's growth. However, biotech stocks Exelixis, Inc. ( EXEL ) , MacroGenics, Inc. ( MGNX ) , and Puma Biotechnology, Inc. ( PBYI ) have been losing momentum lately.",INCY,0.122269,0.047753,Neutral
Innovent Announces 2022 Annual Results and Business Updates,https://www.prnewswire.com/news-releases/innovent-announces-2022-annual-results-and-business-updates-301783693.html,2023-03-29 00:00:00,Building an Innovative Biopharmaceutical Company with Sustainable Growth and Comprehensive Capability,INCY,0.063258,0.102421,Neutral
Innovent Announces 2022 Annual Results and Business Updates,https://www.prnewswire.com/apac/news-releases/innovent-announces-2022-annual-results-and-business-updates-301783698.html,2023-03-29 00:00:00,Building an Innovative Biopharmaceutical Company with Sustainable Growth and Comprehensive Capability,INCY,0.063258,0.102421,Neutral
Incyte's  ( INCY )  Pemazyre Gets Approval to Treat MLNs in Japan,https://www.zacks.com/stock/news/2070932/incytes-incy-pemazyre-gets-approval-to-treat-mlns-in-japan,2023-03-27 16:27:00,Incyte (INCY) receives approval for treating myeloid or lymphoid neoplasms using Pemazyre (pemigatinib) in Japan.,INCY,0.528919,-0.050173,Neutral
"Company News for Mar 27, 2023",https://www.zacks.com/stock/news/2070789/company-news-for-mar-27-2023,2023-03-27 13:37:00,Companies in The News Are: ...,INCY,0.674691,-0.288567,Somewhat-Bearish
Novo Hits Record High On Scorching Ozempic Obesity Battle,https://www.investors.com/news/technology/novo-nordisk-stock-hits-a-record-high-as-ozempic-obesity-battle-heats-up/,2023-03-24 18:37:38,Novo Nordisk Stock Hits A Record As Ozempic Obesity Battle Heats ... Investor's Business Daily ...,INCY,0.124164,-0.120247,Neutral
"Stocks making the biggest moves midday: Block, Deutsche Bank, GameStop, Activision and more",https://www.cnbc.com/2023/03/24/stocks-making-the-biggest-moves-midday-sq-db-gme-atvi-and-more.html,2023-03-24 17:05:09,These are the stocks posting the largest moves in midday trading.,INCY,0.245339,-0.359397,Bearish
Why Incyte  ( INCY )  Shares Are Falling Today - Incyte  ( NASDAQ:INCY ) ,https://www.benzinga.com/general/biotech/23/03/31492989/second-setback-for-incytes-limber-program-analyst-says-resolution-timelines-unclear-to-assess-imp,2023-03-24 15:28:37,"The FDA issued a complete response letter ( CRL ) to Incyte Corporation INCY ruxolitinib extended-release ( XR ) tablets, a JAK1/JAK2 inhibitor, for once-daily ( QD ) use for certain types of myelofibrosis ( MF ) , polycythemia vera ( PV ) and graft-versus-host disease ( GVHD ) .",INCY,0.512093,0.198281,Somewhat-Bullish
How A Surprise Rejection Undercut This Biotech Stock,https://www.investors.com/news/technology/incyte-stock-dives-on-surprise-rejection-for-updated-jakafi/,2023-03-24 13:17:15,Incyte Stock Dives On Surprise Rejection For Updated Jakafi ... Investor's Business Daily ...,INCY,0.854693,0.253272,Somewhat-Bullish
"Stocks making the biggest moves premarket: Deutsche Bank, Coinbase, Block, Marathon Oil and more",https://www.cnbc.com/2023/03/24/stocks-making-the-biggest-moves-premarket-db-coin-sq-mro.html,2023-03-24 12:00:40,These are the stocks posting the largest moves in early morning trading.,INCY,0.109956,-0.044858,Neutral
Incyte  ( INCY )  Gets CRL for Jakafi Extended-Release Tablets,https://www.zacks.com/stock/news/2070048/incyte-incy-gets-crl-for-jakafi-extended-release-tablets,2023-03-24 11:14:00,"The FDA issues a complete response letter to Incyte's (INCY) extended-release tablet formulation of Jakafi drug for the treatment of myelofibrosis, polycythemia vera and graft-versus-host disease.",INCY,0.714462,0.181389,Somewhat-Bullish
"Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval",https://www.zacks.com/stock/news/2069798/biotech-stock-roundup-alt-obesity-data-gild-exercises-option-incy-drug-approval,2023-03-23 17:51:00,Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.,INCY,0.103035,0.099816,Neutral
Incyte  ( INCY )  Receives FDA Approval for Skin Cancer Treatment,https://www.zacks.com/stock/news/2069786/incyte-incy-receives-fda-approval-for-skin-cancer-treatment,2023-03-23 16:14:00,Incyte (INCY) gets accelerated approval for retifanlimab-dlwr for the treatment of adults with metastatic or recurrent locally advanced merkel cell carcinoma.,INCY,0.553883,0.345901,Somewhat-Bullish
"Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval - Incyte  ( NASDAQ:INCY ) ",https://www.benzinga.com/general/biotech/23/03/31471634/incyte-would-now-compete-with-merck-pfizer-as-its-skin-cancer-treatment-scores-fda-accelerated-ap,2023-03-23 11:39:19,The FDA granted accelerated approval to Incyte Corporation's INCY Zynyz ( retifanlimab-dlwr ) for adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma ( MCC ) .,INCY,0.614086,0.463139,Bullish
US FDA grants accelerated approval for Incyte's skin cancer therapy,https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-incytes-therapy-skin-cancer-2023-03-22/,2023-03-22 17:46:00,"March 22 ( Reuters ) - Incyte Corp ( INCY.O ) said on Wednesday its monoclonal antibody, Zynyz, had won accelerated approval from the U.S. health regulator for treating a type of skin cancer in adults. The U.S.",INCY,0.530253,0.163216,Somewhat-Bullish
MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™  ( retifanlimab-dlwr ) ,https://www.globenewswire.com/news-release/2023/03/22/2632605/0/en/MacroGenics-Earns-15-Million-Milestone-Following-U-S-FDA-Approval-of-ZYNYZ-retifanlimab-dlwr.html,2023-03-22 17:22:00,"ROCKVILLE, MD, March 22, 2023 ( GLOBE NEWSWIRE ) -- MacroGenics, Inc. ( NASDAQ: MGNX ) , a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that following the U.S.",INCY,0.177802,0.107954,Neutral
Incyte  ( INCY )  Vitiligo Drug Povorcitinib Positive in Phase II,https://www.zacks.com/stock/news/2068112/incyte-incy-vitiligo-drug-povorcitinib-positive-in-phase-ii,2023-03-20 15:32:00,Incyte (INCY) announces positive data on povorcitinib and Opzelura for the treatment of nonsegmental vitiligo.,INCY,0.458446,0.245741,Somewhat-Bullish
"Analyst Writes Incyte's Opzelura Provides Deepening, Relapse Prevention; Povo Data Intriguing In Depigmented Skin Disorder - Incyte  ( NASDAQ:INCY ) ",https://www.benzinga.com/analyst-ratings/analyst-color/23/03/31420186/analyst-writes-incytes-opzelura-provides-deepening-relapse-prevention-povo-data-int,2023-03-20 14:40:37,"Incyte Corporation INCY announced new data from a Phase 2b trial of povorcitinib ( INCB54707 ) , an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo.",INCY,0.488007,0.036985,Neutral
Why Shares of MacroGenics Climbed Thursday,https://www.fool.com/investing/2023/03/16/why-shares-of-macrogenics-climbed-thursday/,2023-03-16 16:17:29,The cancer-focused biotech delivered a strong earnings report.,INCY,0.1331,-0.011236,Neutral
MacroGenics  ( MGNX )  Q4 2022 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/03/15/macrogenics-mgnx-q4-2022-earnings-call-transcript/,2023-03-16 03:00:35,"MGNX earnings call for the period ending December 31, 2022.",INCY,0.012638,0.058935,Neutral
Agenus  ( AGEN )  Q4 2022 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/03/14/agenus-agen-q4-2022-earnings-call-transcript/,2023-03-14 20:00:41,"AGEN earnings call for the period ending December 31, 2022.",INCY,0.012046,0.156824,Somewhat-Bullish
Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives,https://www.globenewswire.com/news-release/2023/03/14/2626511/8060/en/Agenus-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Outlines-2023-Objectives.html,2023-03-14 11:30:00,"LEXINGTON, Mass., March 14, 2023 ( GLOBE NEWSWIRE ) -- Agenus Inc. ( Nasdaq: AGEN ) , an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today provided a corporate update and reported financial results for the fourth quarter and full year ...",INCY,0.041251,-0.008867,Neutral
"Jefferies retains 'buy' call on Sun Pharma with 26% upside, stays bullish on Concert deal",https://www.moneycontrol.com/news/business/stocks/jefferies-retains-buy-call-on-sun-pharma-with-26-upside-stays-bullish-on-concert-deal-10245781.html,2023-03-14 06:50:39,Jefferies expects Sun Pharma to leverage its existing field force to market this product and incremental spend will largely be towards promotion of the product. It forecasts that Deuruxolitinib can achieve sales of around USD 765 million in the US EU market by 2031.,INCY,0.177802,0.052812,Neutral
Incyte  ( INCY )  Down 8.3% Since Last Earnings Report: Can It Rebound?,https://www.zacks.com/stock/news/2063682/incyte-incy-down-83-since-last-earnings-report-can-it-rebound,2023-03-09 16:30:51,Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,INCY,0.436009,0.119468,Neutral
"Biotech Stock Roundup: PTGX Gains on Study Data, BMRN Faces Setback & More",https://www.zacks.com/stock/news/2063653/biotech-stock-roundup-ptgx-gains-on-study-data-bmrn-faces-setback-more,2023-03-09 16:14:00,Pipeline and regulatory updates from Protagonist (PTGX) and BioMarin (BMRN) are the key highlights from the biotech sector during the past week.,INCY,0.18967,-0.06491,Neutral
"Mesoblast's  ( MESO )  GVHD Drug BLA Gets FDA Priority Tag, Stock Up",https://www.zacks.com/stock/news/2063363/mesoblasts-meso-gvhd-drug-bla-gets-fda-priority-tag-stock-up,2023-03-09 11:58:00,"Mesoblast (MESO) announces the FDA acceptance for review of the resubmitted biological license application for remestemcel-L for the treatment of children under 12 with steroid-refractory acute graft versus host disease. Stock gains on Wednesday, following the news.",INCY,0.161349,0.193188,Somewhat-Bullish
Incyte  ( INCY )  Discontinues Jakafi Combo Myelofibrosis Study,https://www.zacks.com/stock/news/2062555/incyte-incy-discontinues-jakafi-combo-myelofibrosis-study,2023-03-07 14:40:00,Incyte (INCY) decides to scrap the LIMBER-304 study evaluating the efficacy and safety of parsaclisib plus Jakafi for myelofibrosis (MF) following an independent data monitoring committee recommendation.,INCY,0.659096,0.317812,Somewhat-Bullish
Caris Life Sciences and Incyte Enter Into Broad Precision Medicine Partnership to Advance Incyte's Oncology Pipeline,https://www.prnewswire.com/news-releases/caris-life-sciences-and-incyte-enter-into-broad-precision-medicine-partnership-to-advance-incytes-oncology-pipeline-301764183.html,2023-03-07 11:30:00,Caris Life Sciences and Incyte Enter Into Broad Precision Medicine ... PR ...,INCY,0.446546,0.497081,Bullish
Why Incyte  ( INCY )  Shares Are Trading Lower Today - Incyte  ( NASDAQ:INCY ) ,https://www.benzinga.com/general/biotech/23/03/31216736/incyte-discontinues-limber-304-on-doubts-regarding-meeting-primary-goal-analyst-says-it-underpins,2023-03-06 15:50:59,"Incyte Corporation INCY will discontinue the Phase 3 LIMBER-304 trial following the results of a pre-planned interim analysis conducted by an independent data monitoring committee ( IDMC ) , indicating that the study is unlikely to meet the primary endpoint in the intent-to-treat patient ...",INCY,0.478939,0.187972,Somewhat-Bullish
"Why the stock market rally can keep going, says Morgan Stanley strategist who only recently warned of a death zone.",https://www.marketwatch.com/story/why-the-stock-rally-can-keep-going-says-wall-street-strategist-who-only-recently-warned-of-a-death-zone-e51777e9,2023-03-06 11:49:00,"Morgan Stanley's Mike Wilson, who warned of a 'death zone' for investors last month, says at least the short term, this rally can keep going.",INCY,0.082393,0.0,Neutral
Incyte to discontinue late-stage trial for bone marrow cancer drug combination,https://www.reuters.com/business/healthcare-pharmaceuticals/incyte-discontinue-late-stage-trial-bone-marrow-cancer-drug-combination-2023-03-03/,2023-03-03 23:04:00,Incyte to discontinue late-stage trial for bone marrow cancer drug ... ...,INCY,0.235823,-0.332857,Somewhat-Bearish
GILD: 1 Resilient Growth Stock to Buy Now and Hold Forever,https://stocknews.com/news/gild-vrtx-biib-incy-1-resilient-growth-stock-to-buy-now-and-hold-forever/,2023-03-03 17:05:02,"After a brutal 2022, growth stocks are expected to stage a recovery amid cooling inflation, the Fed's downshift on monetary policy tightening, and recent economic data, including strong retail sales and job growth, hinting at the possibility of the economy getting a soft landing.",INCY,0.06623,0.091152,Neutral
GILD: The 3 Best Biotech Stocks to Buy for Under $100,https://stocknews.com/news/gild-incy-taipy-the-3-best-biotech-stocks-to-buy-for-under-100/,2023-03-03 15:05:17,GILD: The 3 Best Biotech Stocks to Buy for Under ...,INCY,0.241284,0.192736,Somewhat-Bullish
"Biotech Stock Roundup: MRNA Q4 Earnings, REGN's Updates, CYTK Receives Setback",https://www.zacks.com/stock/news/2060596/biotech-stock-roundup-mrna-q4-earnings-regns-updates-cytk-receives-setback,2023-03-01 17:24:00,Earnings from Moderna (BIIB) and updates from Regeneron (REGN) are the key highlights from the biotech sector during the past week.,INCY,0.116631,0.200014,Somewhat-Bullish
Merus Announces Financial Results for the Fourth Quarter and Full Year 2022 and Provides Business Update,https://www.globenewswire.com/news-release/2023/02/28/2617716/37568/en/Merus-Announces-Financial-Results-for-the-Fourth-Quarter-and-Full-Year-2022-and-Provides-Business-Update.html,2023-02-28 21:25:00,- Zenocutuzumab ( Zeno ) in NRG1+ cancer potential registrational path and timeline update planned for first half of ...,INCY,0.081001,0.046608,Neutral
Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update,https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-clinical-and-business-update-301758656.html,2023-02-28 21:03:00,Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2022 ... PR ...,INCY,0.057307,-0.024,Neutral
Mirati Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates,https://www.prnewswire.com/news-releases/mirati-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-recent-corporate-updates-301758465.html,2023-02-28 21:01:00,Mirati Therapeutics Reports Fourth Quarter and Full Year 2022 ... PR ...,INCY,0.021484,0.079792,Neutral
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF  ( PBE ) ?,https://www.zacks.com/stock/news/2059096/should-you-invest-in-the-invesco-dynamic-biotechnology-genome-etf-pbe,2023-02-27 11:20:09,Sector ETF report for ...,INCY,0.133841,0.071297,Neutral
"Insider traders have cooked up a new way to leverage secrets, investing at least $3 billion. It's not illegal - but it's probably not making them much money, either.",https://africa.businessinsider.com/markets/insider-traders-have-cooked-up-a-new-way-to-leverage-secrets-investing-at-least/xc4t83m,2023-02-18 10:00:00,Insider traders have cooked up a new way to leverage secrets ... - Business Insider Africa ...,INCY,0.092213,-0.014069,Neutral
Syndax  ( SNDX )  to Report Q4 Earnings: What's in the Cards?,https://www.zacks.com/stock/news/2054138/syndax-sndx-to-report-q4-earnings-whats-in-the-cards,2023-02-14 15:37:00,"Devoid of marketed drugs, investors' focus will be on Syndax Pharmaceuticals' (SNDX) pipeline progress when it reports its fourth-quarter earnings.",INCY,0.243376,0.141808,Neutral
Incyte  ( INCY )  Reports Positive Long-Term Data From HS Study,https://www.zacks.com/stock/news/2053565/incyte-incy-reports-positive-long-term-data-from-hs-study,2023-02-13 17:14:00,Incyte's (INCY) povorcitinib shows sustained and durable efficacy across all treatment arms in the open-label extension period of the phase II HS study.,INCY,0.449219,0.402826,Bullish
"Insider traders use ETFs to front-run M&A deals, academics say",https://www.ft.com/content/9ee4e371-f965-4121-a395-cb8b94a5f9e6,2023-02-13 05:00:14,Research identifies $2.75bn worth of potential 'shadow trades' in US between 2009 and ...,INCY,0.096091,-0.003209,Neutral
"Incyte's Oral JAK Inhibitor Shows Durable Efficacy, Safety At One Year In Skin Disorder - Incyte  ( NASDAQ:INCY ) ",https://www.benzinga.com/general/biotech/23/02/30855041/incytes-oral-jak-inhibitor-shows-durable-efficacy-safety-at-one-year-in-skin-disorder,2023-02-10 14:37:56,"Incyte Corporation INCY announced new 52-week results from a Phase 2 study evaluating the efficacy and safety of povorcitinib ( formerly INCB54707 ) , an oral JAK1 inhibitor, in adult patients with hidradenitis suppurativa ( HS ) .",INCY,0.703273,0.200254,Somewhat-Bullish
Incyte  ( NASDAQ:INCY )  Stock Rating Upgraded by StockNews.com,https://www.defenseworld.net/2023/02/10/incyte-nasdaqincy-stock-rating-upgraded-by-stocknews-com.html,2023-02-10 06:40:41,"Incyte ( NASDAQ:INCY - Get Rating ) was upgraded by investment analysts at StockNews.com from a ""buy"" rating to a ""strong-buy"" rating in a research note issued on Wednesday.",INCY,0.884889,0.447867,Bullish
"Incyte's  ( INCY )  Q4 Earnings, Revenues Top on Jakafi, Opzelura",https://www.zacks.com/stock/news/2051064/incytes-incy-q4-earnings-revenues-top-on-jakafi-opzelura,2023-02-07 15:50:00,Incyte (INCY) reports better-than-expected Q4 results on strong demand for lead drug Jakafi and recently approved Opzelura.,INCY,0.466137,0.369921,Bullish
"Two Top-Notch Medical Stocks Beat Earnings, But Only One Surged",https://www.investors.com/news/technology/incyte-stock-crumbles-despite-earnings-beat-as-haemonetics-wavers/,2023-02-07 15:05:00,"Incyte Stock Crumbles Despite Earnings Beat, As Haemonetics ... Investor's Business Daily ...",INCY,0.70826,0.117119,Neutral
Why Incyte  ( INCY )  Shares Are Trading Lower Today - Incyte  ( NASDAQ:INCY ) ,https://www.benzinga.com/analyst-ratings/analyst-color/23/02/30765250/incyte-q4-earnings-beat-street-view-but-guidance-is-conservative-says-analyst,2023-02-07 15:00:13,"Incyte Corporation's INCY Q4 adjusted EPS reached $0.62, compared to $0.10 posted a year ago. Analysts had estimated $0.58. Q4 total revenues increased by 7% Y/Y to $926.7 million, beating the consensus of $881.10 million.",INCY,0.600602,0.499348,Bullish
Incyte  ( INCY )  Tops Q4 Earnings and Revenue Estimates,https://www.zacks.com/stock/news/2050845/incyte-incy-tops-q4-earnings-and-revenue-estimates,2023-02-07 13:25:08,"Incyte (INCY) delivered earnings and revenue surprises of 5.08% and 4.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?",INCY,0.40348,0.174897,Somewhat-Bullish
"Biotech Stocks' Q4 Earnings Due on Feb 7: VRTX, INCY and EXEL",https://www.zacks.com/stock/news/2050425/biotech-stocks-q4-earnings-due-on-feb-7-vrtx-incy-and-exel,2023-02-06 15:30:00,"Let us take a look at what is in store for some of the biotech stocks VRTX, INCY and EXEL, which are scheduled to report on Feb 7.",INCY,0.317527,-0.199925,Somewhat-Bearish
2 Steady Stocks to Buy in a Recession,https://www.fool.com/investing/2023/02/03/2-steady-stocks-to-buy-in-a-recession/,2023-02-03 14:00:00,Both companies are performing better than the broader market over the past year.,INCY,0.369456,0.076812,Neutral
"Lilly  ( LLY )  Beats on Q4 Earnings, Lags on Sales, Raises '23 View",https://www.zacks.com/stock/news/2049148/lilly-lly-beats-on-q4-earnings-lags-on-sales-raises-23-view,2023-02-02 19:03:00,Eli Lilly's (LLY) earnings surpass fourth-quarter estimates while sales slightly miss the mark. The company raises its EPS guidance for 2023.,INCY,0.032382,-0.045715,Neutral
Dr. Andi Grant is appointed to CEO at BioOra,https://www.prnewswire.com/news-releases/dr-andi-grant-is-appointed-to-ceo-at-bioora-301736961.html,2023-02-02 16:43:00,"MIAMI and WELLINGTON, New Zealand, Feb. 2, 2023 /PRNewswire/ -- BioOra Limited, a Bridgewest Group portfolio company, appoints new CEO, Dr. Andi Grant. Dr. Grant has an accomplished career in global pharmaceutical and biotech businesses, driving the development and commercialization of medical ...",INCY,0.054483,0.130007,Neutral
3 Reasons Why Growth Investors Shouldn't Overlook Incyte  ( INCY ) ,https://www.zacks.com/stock/news/2047906/3-reasons-why-growth-investors-shouldnt-overlook-incyte-incy,2023-02-01 17:45:05,Incyte (INCY) could produce exceptional returns because of its solid growth attributes.,INCY,0.584103,0.484753,Bullish
Incyte  ( INCY )  to Report Q4 Earnings: What's in the Cards?,https://www.zacks.com/stock/news/2047086/incyte-incy-to-report-q4-earnings-whats-in-the-cards,2023-01-31 15:31:00,Incyte's (INCY) fourth-quarter 2022 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.,INCY,0.723597,0.209958,Somewhat-Bullish
"With 14.1% CAGR, Monoclonal Antibody Therapy Market Size Worth USD 451.89 Billion by 2028",https://www.benzinga.com/pressreleases/23/01/g30618366/with-14-1-cagr-monoclonal-antibody-therapy-market-size-worth-usd-451-89-billion-by-2028,2023-01-30 10:54:18,"Pune, India, Jan. 30, 2023 ( GLOBE NEWSWIRE ) -- The global monoclonal antibody therapy market size was USD 157.33 billion in 2020. The market is projected to grow from USD 178.50 billion in 2021 to USD 451.89 billion in 2028 at a CAGR of 14.1% in the 2021-2028 period.",INCY,0.035983,0.085348,Neutral
Incyte  ( INCY )  is a Great Momentum Stock: Should You Buy?,https://www.zacks.com/stock/news/2045640/incyte-incy-is-a-great-momentum-stock-should-you-buy,2023-01-27 17:00:07,Does Incyte (INCY) have what it takes to be a top stock pick for momentum investors? Let's find out.,INCY,0.60326,0.389846,Bullish
Sun Pharma: Speciality pipeline gets a boost | The Financial Express,https://www.financialexpress.com/market/sun-pharma-speciality-pipeline-gets-a-boost/2956734/,2023-01-22 21:00:00,Sun Pharma: Speciality pipeline gets a boost The Financial Express ...,INCY,0.072655,0.065892,Neutral
"Incyte Clears Technical Benchmark, Hitting 80-Plus RS Rating",https://www.investors.com/ibd-data-stories/incyte-clears-technical-benchmark-hitting-80-plus-rs-rating/,2023-01-19 08:00:00,"On Thursday, Incyte ( INCY ) hit a key performance benchmark, with its Relative Strength ( RS ) Rating jumping into the 80-plus percentile with an upgrade to 82, an increase from 78 the day before. X When looking for the best stocks to buy and watch, one factor to watch closely is relative ...",INCY,0.636698,0.337193,Somewhat-Bullish
Incyte  ( INCY )  Up 7% in a Year: Will the Momentum Continue?,https://www.zacks.com/stock/news/2040114/incyte-incy-up-7-in-a-year-will-the-momentum-continue,2023-01-17 14:36:00,Incyte (INCY) outperforms the biotech industry in the past year and the momentum is anticipated to continue in 2023 as well.,INCY,0.63935,0.263315,Somewhat-Bullish
9 Companies' Profit Set To Triple While S&P 500 In Freefall,https://www.investors.com/etfs-and-funds/sectors/9-companies-profit-set-to-triple-while-sp-500-in-free-fall/,2023-01-10 13:00:00,You might think fourth quarter earnings reports are ugly if you're just looking at the S&P 500 itself. But there's more than a few stocks bucking the trend.,INCY,0.195287,0.274608,Somewhat-Bullish
CORRECTING and REPLACING --Merus Provides 2023 Outlook - Merus  ( NASDAQ:MRUS ) ,https://www.benzinga.com/pressreleases/23/01/g30328421/correcting-and-replacing-merus-provides-2023-outlook,2023-01-09 11:05:00,"As of year-end 2022, more than 150 patients with NRG1 gene fusion positive ( ""NRG1+"" ) cancer have been treated with zenocutuzumab ( ""Zeno"" ) monotherapy Petosemtamab clinical update planned for first half of 2023 MCLA-129 clinical update planned for second half of 2023",INCY,0.063383,0.026201,Neutral
CORRECTING and REPLACING --Merus Provides 2023 Outlook,https://www.globenewswire.com/news-release/2023/01/09/2584931/37568/en/CORRECTING-and-REPLACING-Merus-Provides-2023-Outlook.html,2023-01-09 11:05:00,"In a release issued January 8, 2023 by Merus N.V. ( Nasdaq:MRUS ) with the same headline, an error was made stating Merus plans to provide a regulatory path and program update on petosemtamab in the second half of 2023, which has been corrected to indicate this update is planned for the first ...",INCY,0.062967,0.02619,Neutral
Merus Provides 2023 Outlook,https://www.globenewswire.com/news-release/2023/01/08/2584730/37568/en/Merus-Provides-2023-Outlook.html,2023-01-08 14:00:00,"- As of year-end 2022, more than 150 patients with NRG1 gene fusion positive ( ""NRG1+"" ) cancer have been treated with zenocutuzumab ( ""Zeno"" ...",INCY,0.06646,0.026305,Neutral
Geron Corp's blood cancer drug succeeds in late-stage study,https://www.reuters.com/business/healthcare-pharmaceuticals/geron-corps-blood-cancer-drug-succeeds-late-stage-study-2023-01-04/,2023-01-04 12:20:00,Jan 4 ( Reuters ) - Geron Corp ( GERN.O ) said on Wednesday its experimental blood cancer drug helped more patients achieve independence from blood transfusions when compared with a placebo in a late-stage trial. The company's shares were up 63% at $3.90 in premarket trading.,INCY,0.12546,-0.046701,Neutral
Propulsion of Pancreatic Cancer Pipeline as Novel and Extensive 170+ Therapies Likely to Enter in the Treatment Domain | DelveInsight,https://www.prnewswire.com/news-releases/propulsion-of-pancreatic-cancer-pipeline-as-novel-and-extensive-170-therapies-likely-to-enter-in-the-treatment-domain--delveinsight-301711743.html,2023-01-02 15:30:00,Propulsion of Pancreatic Cancer Pipeline as Novel and Extensive ... PR ...,INCY,0.033351,-0.015509,Neutral
